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ABSTRACT  
The development of vaccines remains a valuable tool for the prevention of many 
infectious diseases. First vaccines were either attenuated or inactivated organisms. Subunit 
vaccines were then introduced as more refined formulations, exhibiting improved safety 
profiles. However, purified antigens tend to be poorly immunogenic and often require the use 
of adjuvants to achieve adequate stimulation of the immune system. Some of the latest 
players arrived to the field of adjuvant development are the cyclic di-nucleotides. These are 
ubiquitous prokaryotic intracellular signalling molecules that are not produced by eukaryotic 
cells, which make them to act as danger signals. Previous studies demonstrated that bis-
(3‟,5‟)-cyclic dimeric guanosine monophosphate (c-di-GMP) exhibits potent adjuvant activity 
when administered by systemic or mucosal route. The first part of this thesis is focused on 
the evaluation of two other members of this family, namely bis-(3′,5′)-cyclic dimeric 
adenosine monophosphate (c-di-AMP) and bis-(3‟,5‟)-cyclic dimeric inomisine 
monophosphate (c-di-IMP), as mucosal adjuvants. It is demonstrate that the novel cyclic di-
nucleotides also exhibit strong activity as mucosal adjuvants. Intranasal immunization of 
mice with c-di-GMP, c-di-AMP or c-di-IMP co-administered with the model antigens ß-
galactosidase (ß-Gal) or ovalbumin (OVA) resulted in significantly higher serum antigen-
specific IgG titres and a higher production of antigen-specific secretory IgA (sIgA) in different 
mucosal territories, as compared with vaccination with antigen alone. In addition, strong 
cellular immune responses were also observed against both the ß-Gal protein and a peptide 
encompassing its MHC class I-restricted epitope, respectively. The ratio of ß-Gal specific 
antibodies IgG1 versus IgG2a and the profiles of the cytokines secreted by in vitro re-
stimulated splenocytes suggested that a balanced Th1/Th2/Th17 response pattern is 
promoted by all three cyclic di-nucleotides. However, c-di-AMP showed more potency in 
terms of its in vivo and in vitro activities, being able to activate murine and, particularly, 
human dendritic cells (DCs) and macrophages. Therefore, the second part of this thesis was 
focused on the identification of the targeted cell types and putative molecular mechanism of 
action of c-di-AMP. The obtain results showed a strong activation of different DC subsets and 
a specific production of IL-12 and IL-10 by conventional DCs (cDCs) after c-di-AMP 
activation. Functional studies performed with c-di-AMP showed the adjuvant accumulating 
intravesicular in early endosomes and lysosomes of DCs as well as the activation of the 
MAPK pathways p38α and ERK in DCs and macrophages (MΦs). Moreover, in vivo studies 
on cell specific IFN-ß reporter mice revealed that the adjuvant is also able to trigger a type I 
IFN response in DCs and monocytes/ MΦs.     
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1. CHAPTER: INTRODUCTION 
 
 
1.1 The immune system 
 
1.1.1 Innate immune system 
      One of the most important functions of the immune system is the identification 
and clearance of a wide variety of dangerous entities, such as microbial pathogens, thereby 
protecting the host against diseases [1]. This is implemented through a network of cells, 
tissues, and organs, which are working together to defend the body against attacks by 
viruses, bacteria or parasites. To this end, there are two major tightly integrated systems: the 
innate immune response (ancient non-specific self-defence system) and the adaptive 
immune system (agent-specific response). The stimulation of an efficient immune response 
against any given infectious agent requires a harmonic interaction between components of 
these two systems [2]. 
 
1.1.1.1     Pathogen recognition in the innate immune response  
   The innate immune system is the first line of the defence system against microbial 
pathogens such as bacteria, fungi and viruses. This system includes physical barriers, such 
as the skin and epithelia, which are equipped with additional chemical features that help to 
restrain microbial invasion, e.g. antibacterial peptides, fatty acids, enzymes and low pH [3]. 
However, once the pathogen has crossed this first line of defence, different innate cells, such 
as dendritic cells (DCs), macrophages (MΦ), granulocytes (e.g., eosinophils, neutrophils), 
and natural killer (NK) cells can recognize them. Since microbial pathogens are evolutionarily 
different from their hosts, they display conserved pathogen associated molecular patterns 
(PAMPs), which in turn can be specifically recognized by pattern recognition receptors 
(PRRs). These receptors represent a large group of conserved receptor molecules like 
intracellular and extracellular TLRs (Toll-like receptors), and the cytosolic NLRs (NOD-like 
receptors) and RLRs (retinoic acid inducible gene-1 (RIG-I)-like receptors) expressed in 
different types of immune cells, such as DCs [4-6]. After binding of pathogenic components, 
PPRs trigger the release of pro-inflammatory cytokines (e.g. interferons), thereby leading to 
the stimulation of an adaptive immune response [7, 8]. By using these effector mechanisms, 
the innate immune system is able to rapidly and non- specifically react stopping invading 
pathogens, however, it cannot induce pathogen-specific and long lasting protective immunity. 
Nevertheless, the activated innate immune system represents the critical bridge for the 
 
  INTRODUCTION 
 
12 
 
subsequent stimulation of specific adaptive immune responses against those microbes that 
pose a threat to the host [9]. The establishment of an adaptive response requires time, but it 
is tailored to specific agents and results in long-term memory. Thus, the innate responses 
prevent immediate death upon infection, whereas the more sophisticated subsequent 
adaptive response cannot only clear the pathogens, but also prevent infection and/or disease 
following re-infection. 
 
1.1.1.2     The role of dendritic cells in the immune system  
    DCs are the main professional antigen-presenting cells (APCs), which derive from 
bone marrow (BM) progenitor cells. They play a critical role in translating the message from 
the innate immune system, being responsible for the initiation of adaptive T and B cell 
responses (Figure 1). Using PRRs for microbial and inflammatory products, DCs respond to 
internalized antigen or PAMPs, either by phagocytosis or endocytosis. After binding of 
pathogenic components to PPRs, immature DCs undergo a maturation process 
characterized by the up-regulation of antigen presenting molecules including major 
histocompatibility complex (MHC) lass I and II, adhesion molecules such as CD11c, CD54 
(ICAM-1), and co-stimulatory molecules including CD80 (B7.1), and CD86 (B7.2) [10]. CD86 
is up-regulated earlier during DC maturation, as compared to the CD80 marker [11]. An 
additional marker of matured DCs in humans is CD83 [12]. Following activation, DCs can 
induce innate and adaptive immune responses, supporting the fight against pathogens. The 
two best-studied defence systems in DCs are the production of protective cytokines like 
interleukin-10 (IL-10), IL-12, IL-18 and type I interferons (IFNs), and the activation and 
expansion of innate and adaptive lymphocytes [8, 9]. Targeting the translation of innate into 
adaptive information by DCs offers new perspectives for manipulating the immune system for 
clinical benefit [8].  
 
  INTRODUCTION 
 
13 
 
 
Figure 1: DCs bridging innate and adoptive immunity.   
Adopted from Tsuneyasu Kaisho, RIKEN Research, 2007 [13] 
 
 
There are two main types of DCs in the murine system: the conventional or classical 
DCs (cDCs) and the plasmacytoid DCs (pDCs). The cDCs consist of different subtypes, 
including CD8+ cDCs (myeloid DCs, mDCs) and CD8- cDCs (lymphoid DCs, lDCs), which 
have a dendritic shape and exhibit typical DC functions such as antigen uptake, processing, 
and presentation [14]. They express different toll like receptors (TLRs) such as TLR-2, -3, -4, 
-7 and -9. After encountering different natural ligands or pathogens for these TLRs, cDCs 
become activated and mature into APCs, secreting cytokines (e.g. IL-12) and activating T 
helper cells, as well as B cells, by presenting them antigens derived from the pathogen. By 
flow cytometry, murine cDC are characterized as CD11c+ CD11b+ B220- [15]. Importantly, 
pDCs express a different profile of the microbial pattern recognition TLRs than cDCs. Human 
and mouse cDCs can express TLR-1, -2, -3, -4, -5, -7, and -8 [16, 17] while pDCs uniquely 
express TLR-7 and TLR-9 in the endosomes [18-20]. Since, it is unconventional in the 
mouse system to isolate DC subpopulations or precursors directly from peripheral blood or 
tissue, due to the small sample size, DCs are mostly generated from bone marrow 
precursors with granulocyte-macrophage colony-stimulating factor (GM-CSF) or the FMS-like 
tyrosine kinase 3 receptor ligand (Flt3L). GM-CSF has led to models of the development of 
cDCs and the stimulation with Flt3L leads to a more appreciated model for studying the origin 
of a mixed pDC and cDC population [14, 21].    
Despite several distinct subtypes of DCs, they all have the ability to engulf antigens in 
their environment by endocytosis using phagocytosis, receptor-mediated endocytosis, and 
pinocytosis [22-24]. Phagocytosis is an essential component of the innate immune response. 
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Phagocytic vacuoles acquire degradative and antimicrobial properties through a complex 
series of interactions with endomembrane. This process, collectively termed phagosome 
maturation, culminates in the fusion of phagosomes with lysosomes, yielding a hybrid 
organelle enriched in hydrolytic enzymes, reactive oxygen species and antimicrobial peptides 
that promote the killing and degradation of internalized microorganisms [25].  
 
1.1.1.3     Type I interferons and their effect on immune cells 
   The type I IFNs consist on a number of structurally homologous proteins including 
13 IFN-α subtypes, a single IFN-β, and other less well characterized proteins. However, the 
role of type I IFNs in the immune system has been characterized in detail only for IFN-α and 
IFN-β [26]. Type I IFNs can be produced by almost any cell type in the body in response to 
microbes by a number of transmembrane and cytosolic receptors. However, in response to 
viral infections, type I IFN is mainly produced by pDCs [27, 28]. Monocytes, which are able to 
differentiate into DCs, could also produce type I IFN, although much less than pDCs, after 
interaction with infectious agents [29]. All type I IFN species interact with the same IFN-α/ß 
cellular receptor (IFNAR), the activation of which triggers several signalling cascades. The 
first signalling pathway described after activation by type I IFNs was the JAK-STAT (Janus 
activated kinase - Signal Transducer and Activator of Transcription) pathway [30]. But there 
are evidences that several other signalling elements and cascades are required for 
responses to type I IFNs, such as the MAPK pathway and others [31]. The different effector 
functions of type I IFNs result in an improved innate immune response, which in turn leads to 
an enhanced adaptive immune response. Furthermore, IFN-α/ß up-regulate the expression 
of the IL-12 receptor b2 chain on CD4+ T cells, thereby facilitating their differentiation into 
IFNγ producing Th1 cells in response to IL-12. 
 
 
1.1.2 Adaptive immune system 
     In contrast to the innate immune system, the adaptive immune system has 
evolved to recognize microorganisms that are able to escape the non-specific defence 
systems of the host. This is achieved by the stimulation of a highly specific and sophisticated 
response. The adaptive immune system manifests exquisite specificity for its target antigens, 
due to antigen-specific receptors expressed on the surfaces of T and B lymphocytes. The 
antigen-specific receptors of the adaptive response are assembled by means of somatic 
rearrangement of germline gene elements to form intact T cell receptor (TCR) and 
immunoglobulin (Ig) genes [2]. In addition to the specificity, the most important difference is 
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the development of memory, which allows a very rapid response of antigen specific effector 
cells upon a second encounter with the relevant antigen from a pathogenic organism. 
T lymphocytes also arise from BM, but unlike the B cells, T cells migrate to the 
thymus gland for maturation. The T cell expresses a unique antigen-binding molecule, the 
so-called TCR, which recognizes only antigens bound to MHC molecules. MHC molecules 
are polymorphic (genetically diverse) glycoproteins found on cell membranes. There are two 
major types of MHC molecules: class I MHC molecules, which are expressed by nearly all 
nucleated cells of vertebrate species, and class II MHC molecules, which are expressed only 
by professional antigen-presenting cells. MHC class I molecules present antigen fragments 
to cytotoxic T cells and will bind to CD8 on cytotoxic T cells, and MHC class II present 
antigen fragments to Th cells by binding to the CD4 receptor on the Th cells. The adaptive 
immune response can be divided into two main arms, namely, cellular and humoral immunity 
[32]. 
 
1.1.2.1 Humoral immunity 
      Humoral immunity is the major defence mechanism against foreign antigens, such 
as extracellular pathogens and toxins. The humoral immune response is mediated by the 
secretion of antibodies, which are produced by B plasma cells, which are derived from B 
lymphocytes. B cell expresses a unique antigen-binding receptor on its membrane after 
leaving the BM where they mature. When a naïve B cell encounters an antigen that matches 
its membrane-bound antibody for the first time, the binding induces antigen specific B cells to 
rapidly divide into many clones of plasma cells and memory B cells. Plasma cells produce 
antibodies in a form that can be secreted and has little or no membrane-bound capacity [32, 
33].  
Antibodies or Ig, are not only receptors on the surface of B cells, but in addition are 
soluble proteins in extracellular fluids (sera, plasma, lymph, mucus, etc.), which are able to 
bind to antigens. This antigen-antibody binding contribute to host protection by three main 
ways: neutralization, opsonisation and complement activation. Neutralization is important in 
preventing bacterial toxins from entering the cells. The coating of the surface of a pathogen 
to enhance the phagocytosis is called opsonisation. Complement activation results in 
complement protein binding to the pathogen surface, and subsequently opsonisation of the 
pathogen by binding complement receptors on phagocytes or direct lysis [34].  
In general, B cells need two signals to become active and to secrete the specific 
antibodies. The first signal is the cross-linking of the B cell-surface bound Ig by antigen. 
However, most antigens are T cell dependent, i.e. T cell help is required for maximal 
antibody production, and the second activation signal is delivered by a Th2 cell. The T cell 
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dependent antigens are taken up by surface-bound antibodies, processed and finally 
antigenic peptides are presented on B cells via MHC class II to antigen-specific Th2 cells. 
These T cells then provide co-stimulation signals, which trigger B cell proliferation and their 
differentiation into plasma cells and memory cells. The first class of antibodies secreted after 
B cell activation are belonging to the IgM isotype. Subsequently, class switching to IgG, IgA, 
IgD and IgE, and the generation of memory B cells occur in response to cytokines [35]. IgG 
and IgA are the predominant and highly specific antibody classes. Most B cells secreting 
these Ig classes have been selected for increased affinity of Ag-binding in germinal centers, 
where they underwent affinity maturation by somatic hypermutation. IgG is the most 
abundant Ig class in plasma in part due to its longer life halftime, whereas IgA is the most 
abundant Ig in secretions [32]. 
 
1.1.2.2 Cellular immunity 
      Cell-mediated immunity (CMI) involves the activation of antigen-specific T 
lymphocytes and their effector functions. The principle role of CMI is to detect and eliminate 
cells that harbour intracellular pathogens. CMI can also recognize and eliminate cells, such 
as tumour cells, which have undergone genetic modification. Both antigen-specific and non-
specific cells can contribute to CMI. Antigen-specific cells include CD8+ cytotoxic T 
lymphocytes (TC cell or CTLs) and cytokine-secreting CD4
+ T cells or Th cells. Non-specific 
cells include NK cells and non-lymphoid cell types such as macrophages, neutrophils and 
eosinophils [32]. Importantly, there are other specialized T cells that express CD4 and CD25 
known as regulatory T cells (Treg cells), or suppressor T cells, which are crucial for the 
maintenance of immunological tolerance. Their major role is to shut down T cell-mediated 
immunity toward the end of an immune reaction and to suppress auto-reactive T cells that 
escaped the process of negative selection in the thymus [36]. 
 CTLs represent essential effector cells, which recognize and are able to kill cells 
expressing foreign peptide antigens in association with MHC class I molecules. The 
response of CTLs is antigen specific and contact dependent. For this purpose, CTLs contain 
membrane-bound cytoplasmic granules filled with proteins, including perforins and 
granzymes, which are capable to cause cell lysis. Furthermore, CTLs are able to protect the 
body by destroying body cells displaying epitopes of foreign antigens on their surface, such 
as virus-infected cells, cells with intracellular bacteria, and cancer cells displaying tumour 
antigens. In addition, activated CTLs cells secrete a variety of cytokines that influence the 
function of other bystander cells involved in innate and adaptive immune responses, such as 
IFN-y [37, 38].  
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CD4+ Th cells are another important cell population of the adaptive immune system 
and can be differentiated into different types of effector subsets with different immunological 
functions. The earlier discovered Th1 and Th2 CD4+ T cells proliferate in response to antigen 
stimulation, thereby leading to the production of IL-2 and its receptor through an autocrine 
loop, which in turn stimulates antibody production and macrophage activation. IFN-y-
producing Th1 cells were presumed to take part in the phagocytic process and the 
intracellular defence against viruses and bacteria. In contrast, Th2 cells, which secrete IL-4, 
IL-5 and IL-13, orchestrate non-phagocytic and extracellular defence against helminths and 
take part in allergic reactions. Th2 cells initiate the humoral immune response by activating 
naïve antigen-specific B cells to produce antibodies. They are essential in determining B cell 
antibody class switching, in the activation and growth of T cells and in maximizing 
bactericidal activity in phagocytes, such as macrophages. These responses are important in 
the defence against parasites and mucosal pathogens. The discovery of the third type of Th 
cells, the Th17 lineage, came later from studies performed using murine models of 
experimental autoimmune encephalitis (EAE) and collagen induced arthritis (CIA). Formerly, 
the autoimmune reactions observed in these models were wrongly attributed to the 
stimulation of a Th1 immune response. This resulted from the observation that EAE or CIA 
was ablated by treatment with neutralizing antibodies specific for the p40 subunit of IL-12, 
the main cytokine responsible for Th1 cells development. However, subsequent studies 
demonstrated that IL-23 shares with IL-12 the p40 subunit [39]. Thus, the IL-12 heterodimer 
is composed of IL-12p40 and IL-12p35 subunits, whereas the IL-23 is formed by IL-12p40 
and IL-23p19. Later studies using knockout (ko) mice showed that the disease develops in 
IL-12-ko mice, but not in IL-23-ko mice [40]. These pioneer studies resulted in a blooming 
interest in the field for elucidating the underlying mechanisms of the development and 
function of Th17 cells. Currently it is known that IL-23 is not important for development of 
Th17 subsets, but it is also required for the maintenance of this CD4+ T cell sub-population 
[41]. The development of Th17 cells is also under negative regulation of IL-2. This diversity in 
Th function and their role in influencing other immune cells pointed to the importance of 
these cells during the course of natural infections. For example, in the Human 
immunodeficiency virus (HIV) infection the virus infects CD4+ cells. This in turn leads to a 
massive decrease of functional CD4+ T cells, thereby resulting in AIDS symptoms [35, 42-
44]. 
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1.1.3 Mucosal immune system 
      The mucosal tissues represent the first line of defence against infection, since it 
constitutes the main entry site for most microbial pathogens. Therefore, components of the 
highly specialized innate and adaptive immune system protect the mucosal surfaces and 
body interior from potential injuries. This local immune system contributes to almost 80% of 
all immune cells. The cells are accumulated in, or transit between the mucosa-associated 
lymphoid tissues (MALT), which as a whole represents the largest mammalian lymphoid 
organ (Figure 2) [26]. MALT includes the intestinal mucosa (Gut-Associated Lymphoid 
Tissue, GALT) and the respiratory tract (Nasal-Associated Lymphoid Tissue, NALT; and 
Bronchus-Associated Lymphoid Tissue, BALT). NALT is composed of a bell-shaped 
structure located in the nasal passages above the hard palate of rodents and other mammals 
[45, 46]. In mice NALT organogenesis begins soon after birth and is dependent on several 
factors, including various cytokines and chemokines, as well as environmental cues [47]. In 
humans, NALT-like structures are evident at a very young age, but disappeared by the age 
of two years, whereas the Waldeyer's ring, which also includes nasopharyngeal lymphoid 
tissues, persists throughout life [48]. The architecture of NALT is structured like lymph nodes, 
organized into discrete compartments of immature B and T-lymphocytes and antigen-
presenting DCs [49, 50].     
The mucosal immune response has three main functions: (i) protection of the 
mucosal surface against colonization and invasion by dangerous microbes, (ii) prevention of 
the uptake of non-degraded antigens, including foreign proteins derived from ingested food, 
airborne matter and commensal micro-organisms, and (iii) interference with the development 
of potentially harmful immune responses to these antigens if they reach the body interior [51, 
52]. The MALT functions independently from the systemic apparatus. It is formed by 
anatomically defined lymphoid micro-compartments (Peyer‟s patches, lymph nodes, 
appendix, tonsils and adenoids), which serve as mucosal inductive sites where adaptive 
immune responses are initiated [53].  
An important characteristic of the mucosal adaptive immune response is the local 
production and secretion of IgA and IgM dimers and oligomers in both mice and humans. 
These IgA and IgM polymers originate from the interaction of IgA or IgM monomers with the 
J chain (IgA+J and IgM+J), a polypeptide synthesized by antibody-secreting cells. In 
addition, the J chain interacts with the polymeric Ig receptor (pIgR). The polymeric Ig 
receptor is expressed basolaterally as membrane secretory component (mSC) on secretory 
epithelial cells [54]. The secretory component of sIgA and sIgM protects the Ig from being 
degraded by proteolytic enzymes. The resistance to host proteases makes sIgA uniquely 
suited for functioning in mucosal secretions to protect the body against adhesion and entry of 
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pathogens at mucosal sites. The induction of sIgA is dependent on Th2 cells that produce IL-
4 and IL-10, thereby prompting B cell Ig class switch to IgA and differentiation into IgA 
producing plasma cells (Figure 2) [52]. The number of active subclasses for IgA is different 
among different species. The mouse has only one, but in humans there are two subclasses, 
IgA1 and IgA2, which are characterized by a differential distribution in the body. Indeed, the 
circulating IgA pool is comprised mostly of IgA1, whereas the mucosal IgA pool contains both 
IgA1 and IgA2 [55]. IgA2 is particularly abundant at sites colonized by microbes, including 
the distal intestinal tract and the urogenital tract [56, 57].  
 
Figure 2: Mucosal Immunity.  
Mucosal surfaces (A) constitute the largest interface between the body and the external environment, including 
the respiratory (purple), gastrointestinal (green) and genital (blue) tracts. Mucosal immune response (B) 
pathogen surveillance is mediated by specialized antigen transport cells (M-cells) and antigen processing cells 
(DCs) (1). Mucosal DCs are particularly important at initiating adaptive immune responses by migrating to the 
draining lymph node and mediating the expansion of antigen-specific naïve T-cells into Th subsets (Th1, Th2, 
Th17, or T regulatory cells). (2), involving an up-regulation of transcription factors and lineage-defining cytokines 
(IFN-γ, IL-4, IL-17, TGFβ, IL-35, and IL-10). Expanded T cell subsets will home back to mucosal surfaces to 
perform their effector functions (3). Th17 cells and IL-17 expression can up-regulate polymeric Ig (pIg) receptor 
humoral defense mechanism mucosal CTLexpression and IgA class switching, enhancing IgA secretion (4). In 
addition, soluble factors secreted by DCs and epithelial cells can promote T-cell Independent IgA class switching 
(5). Increased IgA production and translocation through epithelial cells hinders pathogen invasion and promotes 
immunity at mucosal surfaces. Adopted from Lawson et al., Current Opinion in Immunology, 2011 [58] 
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The CTLs present in the mucosal tissue also have a crucial role in the clearance or 
containment of mucosal viral infections [59]. Protective mucosal immune responses are most 
effectively induced by mucosal immunization via nasal, oral, rectal or vaginal routes [60]. The 
nasal mucosa is an important inductive site of the mucosal immune system, since this site is 
the first port of entry for inhaled pathogens.  
The nasal mucosa is an important compartment within the mucosal immune system, 
since this site is the first port of entry for inhaled pathogens. Furthermore, there is an 
induction of CTLs in distinct mucosal tissues. More interesting, there is a significant degree 
of compartmentalization linking specific mucosal inductive sites with particular effective sites. 
Depending on the choice of vaccination route an effective immune responses can be induced 
at the desire sites. Thus, rectal immunization evokes strong local IgA antibody responses in 
the rectum, whereas nasal or tonsilar immunization in humans results in antibody responses 
in the upper airway mucosa and regional secretions (salvia, nasal secretions). This is 
attractive for the development of vaccines against sexual transmitted diseases [52, 61].    
 
 
 
1.2 Vaccination 
Vaccination works by inducing a pathogen-specific immune response through the 
administration of vaccine antigens, which enable the stimulation of memory cells that could 
later recognize and respond to a similar organism before it could cause disease. Vaccination 
has been and still is one of the most important public health interventions in history. The 
practice of immunizing to confer protection against disease can be traced to as early as the 
7th century when Indian Buddhists drank snake venom to induce immunity, possibly through 
a toxoid-like effect. Immunization (i.e. the act of protecting against disease by introducing an 
antigen into the body to induce immunity) against smallpox probably began early in the 1022 
to 1063 AD in central Asia and then spread to China and west Turkey [62]. Smallpox used to 
be a common disease throughout the world and 20 to 30% of infected persons died from the 
disease. Smallpox was responsible for 8 to 20% of all deaths in several European countries 
in the 18th century. Other experiments followed, but Edward Jenner´s could show in the 18th 
century, that immunization with the less dangerous cowpox could protect against infection 
with smallpox. This experiment inspired indeed the word vaccination, which is derived from 
vacca, the Latin word for cow [63, 64]. In the 19th century Louis Pasteur developed the 
concepts of attenuation, modification through passage, renewed virulence and the need to 
replace person-to-person vaccination with something safer, more consistent, and less likely 
to transmit other diseases [65].  
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Since those pioneering efforts, vaccines have been developed for many diseases that 
were once major afflictions of mankind. The incidence of diseases such as diphtheria, 
measles, mumps, pertussis (whooping cough), rubella (German measles), poliomyelitis, and 
tetanus has declined dramatically as vaccination has become more common. Despite the 
fact that vaccination is the most cost-effective weapon to prevent infectious diseases [66], 
there are still many diseases for which vaccines are not available. Every year, millions of 
individuals die throughout the world from malaria, tuberculosis, AIDS, viral hepatitis, 
respiratory or gastrointestinal infections, just to name a few, because there are no effective 
vaccines or the available vaccines cannot reach those in need. For example, it is estimated 
by the World Health Organization (WHO) that every day 15,000 people, mainly young adults 
become infected with HIV (e.g. Figure 1). An effective vaccine could have an immense 
impact in the control of the spread of HIV/AIDS [66]. 
 
1.2.1 Vaccines  
Recent advances in immunology and molecular biology has led to the development of 
novel vaccines with satisfactory efficacy and safety profiles. The identification of T and B cell 
epitopes has also enabled immunologists to design new vaccine candidates, which are able 
to stimulate both arms of the immune system. Vaccines can be roughly classified into 
different types. Live attenuated vaccines, such as some paediatric vaccines (e.g. measles, 
mumps, rubella, oral polio and BCG) stimulate the immune system via a transient infection 
caused by replicating live organisms without causing clinical illness. However, they are able 
to cause diseases in immune compromised individuals. Thus, a safer vaccination approach 
is based on the use of inactivated organisms (e.g. inactivated vaccines against polio or 
whooping cough) or non-replicating subcellular components, the so-called subunits (e.g. 
subunit vaccines against polio and hepatitis B virus). Well defined vaccines based on 
selected subcellular components are very attractive, since the immune stimulus is maximally 
directed to the molecule that is relevant for stimulating protection. However, the identification 
of an essential immunogenic component which is able to promote protective responses is 
complicated and many pathogens have evolved antigenic variation as escape mechanism. In 
addition, these vaccines are usually less reactogenic than whole-cell vaccines, but also 
considerably less immunogenic. Therefore, they often require additional components known 
as adjuvants in the formulation, which stimulate the immune system and potentiate/modulate 
antigen-specific responses, while having little or no antigenicity on their own [67-71]. 
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1.2.2 Adjuvants 
Adjuvants (adjuvare (latin) = to help) have been traditionally used to increase the 
magnitude of an adoptive response to a vaccine, but a second role for adjuvants has become 
increasingly important: namely, guiding the type of adoptive response to produce the most 
effective form of response for each specific pathogen. Therefore, there are different 
mechanisms of action which are reported to contribute to the biological activity of adjuvants 
incorporated into vaccines [69]. They can (i) provide an antigen depot, thereby creating an 
antigenic reservoir for slow release; (ii) facilitate the antigen targeting to antigen presenting 
cells; (iii) promote antigen processing and presentation; and (iv) create a microenvironment 
conductive towards modulation and enhancement of the elicited immune response [72, 73]. 
Adjuvants also provide a danger signal that tells the immune system that a particular antigen 
cannot be ignored. The use of particular adjuvants offers the possibility to improve the 
efficiency of mucosal applied vaccines [74]. An ideal adjuvant should be stable, 
biodegradable, cheap, poorly immunogenic by itself and able to promote strong immune 
responses of a well-defined type [72, 75]. Adjuvants can be broadly divided into two groups 
based on their principal mode of action: delivery systems and immunostimulatory molecules. 
Delivery systems (mineral salts, oil-in-water emulsions, virosomes and liposomes) are mainly 
enhancing the uptake of antigens by APCs, whereas immunostimulatory molecules induce a 
rapid activation of innate immunity. Many of the immunostimulators are sensed by various 
members of the TLR family, a subclass of PPRs. They may also exert dual or overlapping 
effector functions [72, 76]. Nevertheless, this distinction is arbitrary, since a considerable 
body of experimental evidence is accumulating, demonstrating that even adjuvants which 
were traditionally considered as promoters of delivery (e.g. aluminium salts [alum]) exhibit 
important immune modulatory properties.   
Overall, several hundred of natural and synthetic compounds have been identified, 
but only a few are licensed for human use, such as alum, oil-in water emulsions (MF59 and 
AS03), and monophosphoryl lipid A (MPL; a non-toxic derivative of the TLR-4 agonist 
lipopolysaccharide) plus alum (AS04) [68, 74]. Others are in widespread experimental use or 
in late stage clinical development (Table 1) [72].  
It is clear that novel adjuvants will be required to enable the successful development 
of innovative vaccines. Both components, antigen and adjuvants, are of critical importance in 
order to induce an immune response that will protect against diseases for which traditional 
approaches have failed, such as HIV and Hepatitis C virus (HCV) [77, 78].  
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Table 1: Adjuvants licensed for human vaccines or under clinical development 
Adjuvant Formulation 
Type of Immune 
Response 
Vaccines Reference 
Alum 
Non-crystalline gels based on 
aluminum oxyhydroxide or 
hydrooxyphosphat  
Th2  
HBV*, HAV*, HPV*, 
diphtheria-tetanus, 
haemophilus influenza B, 
inactivated polio virus, etc. 
[79, 80] 
MF59, AS03 
Squalene-based oil-in-water 
emulsion 
Th1 and Th2 
HSV, HIV, influenza (Fluad), 
pandemic flu (Pandemrix) 
[80-82] 
AS04 MPL absorbed on alum  Th1 HBV, HAV, HPV, Flu [80] 
CTB Cholera toxin B subunit Th1 and Th2 
Orally delivered cholera 
vaccine (Dukoral, Shanchol, 
Orochol) 
[83, 84] 
Advanced Development  
Poly(I:C) 
Synthetic derivatives of 
dsRNA 
Th1, CD8
+
 T cells Flu, cancer [72, 85, 86] 
MPL and 
formulations 
(AS01, AS02) 
MPL and QS-21  Th1 and Th2 Malaria, TB*, cancer [80, 87] 
CpG*  
Oligonucleotide + alum, 
oligonucleotide + MF59, 
oligonucleotide 
Th1, CD8
+
 T cells 
(when conjugated) 
HBV, malaria, HVC, cancer  [88, 89] 
ISCOMS and 
ISCOMATRIX 
Phospholipids, cholesterol, 
QS-21 
Th1 and Th2, CD8
+
 T 
cells 
HCV, HSV*, HBV, HIV* 
influenza, malaria, cancer 
[80, 89] 
IC31 KLK* with ODN Th1, B-cell responses Influenza, TB, HCV*  [90, 91] 
*HBV = Hepatitis B virus; HAV = Hepatitis A virus; HPV = Human papillomavirus; HSV = Herpes simplex virus; TB = 
tuberculosis; HIV = human immunodeficiency virus; HCV = Hepatitis C virus; CpG = CpG oligodeoxynucleotidesQS; KLK = anti-
microbial peptide 
 
 
1.2.3 Mucosal vaccination and adjuvants  
Mucosal immune responses are most efficiently induced by administration of vaccines 
onto mucosal surfaces (e.g. intranasally, orally). This route of immunization does not only 
induce cellular and humoral immune responses at the site of vaccine application, but also 
throughout the body. In addition, mucosal immunizations offer several advantages over 
parenteral administration, e.g. easy administration, lower costs, possibility of self-
administration, avoidance of needle-stick injuries, low rates of local side effects and high 
acceptance (i.e. better compliance) by the public [52, 92]. This makes them particularly 
amenable for implementation in mass vaccination campaigns. 
Despite these advantages, only a few mucosal vaccine candidates were tested, and 
even less reached the market. One mayor problem is still the poor immunogenicity of the 
antigens when administrated by mucosal route due to mechanical removal and structural 
modification by extreme pH and/or enzymatic degradation [93, 94]. To overcome these 
problems many groups tried to develop adjuvants which are able to promote efficient antigen 
specific immune responses at both systemic and local levels. However, there are only a 
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handful of molecules exhibiting this property [95, 96]. In addition, there are serious concerns 
about the safety profile of some of these compounds [97]. Thus, there is still a strong need 
for new candidate adjuvants. 
 
1.2.4 The cyclic di-nucleotides as mucosal adjuvants  
Cyclic di-nucleotides are second messenger molecules of bacterial and archaeal 
origin, which exert their activity by regulating several biological processes. Among them can 
be cited bis-(3',5')-cyclic dimeric guanosine monophosphate (c-di-GMP) and bis-(3',5')-cyclic 
dimeric adenosine monophosphate (c-di-AMP) (Figure 3).  
  
 
 
 
 
 
 
 
 
Figure 3: Chemical structures of cyclic dinucleotides.  
 
The c-di-GMP was first identified as a cellulose synthase activator in 
Glycanocetobacter xylinus [98]. Furthermore, it is essential for the regulation of biofilm 
formation, motility, virulence gene expression and other critical aspects of physiology in a 
number of pathogens [99-108]. High levels of c-di-GMP enhance biofilm formation and 
repress virulence factor expression and motility, whereas low levels of c-di-GMP repress 
biofilm formation and induce virulence factor expression and motility [104, 109]. Karaolis et 
al. showed that exogenous c-di-GMP reduces in vitro cell-cell interactions and biofilm 
formation of Staphylococcus aureus [110] and also demonstrated that treatment with c-di-
GMP attenuates S. aureus infection in vivo, reducing bacterial loads in a mouse infection 
model [111]. Recent reports have described another compound of the cyclic di-nucleotide 
family, c-di-AMP, which represents a novel second messenger, which signals for DNA 
integrity in Bacillus subtilis during sporulation [112]. During the time in which the 
experimental work of this thesis was carried out, c-di-AMP was also identified as molecule 
secreted by Listeria monocytogenes, which is able to trigger the cytosolic innate host 
response [113, 114]. However, it remains still unclear the evolutionary advantage resulting 
from c-di-AMP expression for Listeria spp. Nevertheless, the role played by c-di-AMP in 
Listeria spp. seems to be totally different from the function in B. subtilis, thereby indicating 
c-di-AMP c-di-IMPc-di-GMP
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diverse evolutionary pathways and roles of this second messenger in bacteria. Since they 
seem to be crucial for bacterial survival, it can be assumed that these molecules could serve 
as danger signals recognized by the host immune system. It can be argue that other 
structurally related compounds could act as danger signals able to evoke an immune 
response in the host. An example of this is the bis-(3',5')-cyclic dimeric inosine 
monophosphate (c-di-IMP) (Figure 3), which can be synthesized as a derivative of the 
parental compound c-di-AMP through adenosine-deamination.  
 
 
1.3 Aims of the study  
The first aim of this doctoral thesis was to perform a comparative evaluation of the 
immune modulatory properties of c-di-GMP, c-di-AMP and c-di-IMP to select the most 
promising candidate adjuvant for further development. The second aim was to perform in 
depth in vitro experiments using cells of murine and human origin, as well as ex vivo and in 
vivo studies in mice to identify the target immune cells and underlying mechanisms of action 
of the resulting compound.   
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2. CHAPTER: MATERIALS AND METHODS  
 
2.1 MATERIALS 
 
2.1.1     Chemical and reagents 
Table 2: Chemical components and reagents 
Chemical agent or reagent Manufacturer/Distributor 
51
Chromium (chromate solution) Amersham, Germany 
ABTS (2,2`-azino-bis (3 ethhylbenzthioazoline-6-sulfonic acid) Sigma-Chemie, Germany 
AEC substrate kit (3-amino-9-ethyl-cabazole) BD Pharmingen
TM
, USA 
Acetic acid (CH3COOH) Merck, Germany 
Ampuwa® Serumwerk, Germany 
Avidin-HRP (horseradish peroxidase) conjugated (ELISPOT) BD Pharmingen
TM
, USA 
Ammonium chloride (NH4Cl)  Merck, Germany 
Beta-galactosidase protein (ß-Gal) Roche, Germany 
BSA (Bovine serum albumin)               Sigma-Chemie, Germany 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) Invitrogen, Germany 
Citric acid –1- hydrate (C6H8O7 * H2O) Riedl-de-Haën, Germany 
DMEM medium (low Glucose, 0.1 g/L ) Gibco, UK 
DMEM medium (high Glucose, 4.5 g/L) Gibco, UK 
DMF (N,N-dimethylformamide) Sigma-Aldrich, Germany 
DMSO  (dimethyl sulfoxide) Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Fluka, Switzerland 
Ethanol 100% Fluka, Switzerland 
FCS (fetal calf serum, South America)  Greiner Bio-One, USA 
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FLT3L  (Fms-like tyrosine kinase 3 ligand) BD Pharmingen
TM
, USA 
Formaldehyde ≥ 36.5% Riedl-de-Haën, Germany 
Gentamycine (50mg / ml in deionised water) Gibco, UK 
GM-CSF (granulocyte-macrophage colony stimulating factor) BD Pharmingen
TM
, USA 
L-Glutamine  Gibco, UK 
Isofluran
®
Curamed vet inhalation anesthetic  Essex Tierarznei, Germany 
Isopropanol Merck, Germany 
LPS (Lipopolysaccharide) Sigma-Aldrich Germany 
M-CSF (macrophage colony stimulating factor) BD Pharmingen
TM
, USA 
2-Mercaptoethanol (50 mM) Gibco, UK 
[methyl-
3
H] Thymidine solution Amersham, Germany 
OVA (Ovalbumin) Sigma-Aldrich Germany 
Paraformaldehyde (PFA) Merck, Germany 
Penicillin/Streptomycin (100 units/ml Penicillin G sodium; 50 μg/ml 
streptomycin sulphate in 85% Saline) 
Gibco, UK 
PMSF (phenylmethylsulfonylfluoride) Carl Roth GmbH, Germany 
Potassium chloride (KCl)  Fluka, Switzerland 
Potassium hydrogen carbonate (KHCO3)  Merck, Germany 
Potassium dihydrogen phosphate (KH2PO4)  Carl-Roth, Germany 
RPMI 1640 medium (L-glutamine)             Gibco, UK 
Saponin  Sigma-Aldrich, Germany 
Sodium acetate (CH3COONa) Merck, Germany 
Sodium carbonate (Na2CO3)  Carl-Roth, Germany 
Sodium chloride (NaCl)  Carl-Roth, Germany 
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Sodium hydrogen carbonate (NaHCO3)  Merck, Germany 
Sodium hydroxide (NaOH) Carl-Roth, Germany 
Streptavidin – horseradish peroxidase conjugate (ELISPOT) BD PharmingenTM, USA 
Streptavidin –HRP 
(horseradish peroxidase) conjugated (ELISA) 
Sigma-Aldrich, Germany 
tri-Sodium citrate   Merck, Germany 
Triton X100 Carl Roth GmbH, Germany 
Trypsin-EDTA (1x) in HBSS Gibco, UK 
Tween 20  Carl-Roth, Germany 
 
 
2.1.2 Solutions and buffers 
Table 3: Solutions and buffers 
Solution / buffer Composition 
ABTS-solution 0.3 g/l ABTS in 0.1 M citric acid 
Acetate solution (0.1 mM) 
148 ml acetic acid 0.2 mM to 352 ml of 0.2 mM sodium acetate; adjust 
volume to 1 l with water, ph 5.0 
ACK lysis buffer 0.1 mM EDTA; 1 mM KHCO3; 155 mM NH4Cl; pH 7.3 
Carbonate buffer for ELISA 1.59 g/l Na2CO3; 2.93 g/l NaHCO3; pH 9.6 
FACS-buffer 1% BSA/PBS (w/v) 
Lavage buffer 5% FCS/PBS (v/v) 
Paraformaldehyde 2% (w/v) in PBS; pH 7.0 (tissue fixation) 
PBS (phosphate-buffered saline) 2.7 mM KCl; 1.8 mM KH2PO4; 137 mM NaCl; 10 mM Na2HPO4; pH 7.4 
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2.1.3 Cell culture media 
Table 4: Cell culture media 
Medium Supplements 
D-MEM for DC 
10% FCS heat inactivated; 100 Units/ml penicillin; 50 µg/ml  
streptomycin; 1mM L-glutamine; 50 µg/ml gentamycine  
D-MEM for MΦ 
10% FCS heat inactivated; 100 Units/ml penicillin; 50 µg/ml  
streptomycin; 1mM L-glutamine; 5% horse serum; 20% L929-conditional medium (M-CSF) 
Freezing medium FCS heat inactivated + 10% DMSO 
RPMI  complete 
RPMI 1640 supplemented with 10% FCS heat inactivated; 100 
units/ml penicillin; 50 μg/ml streptomycin; 1 mM L-glutamine; 2.5 x  
10
-2
 M 2-mercaptoethanol 
 
 
2.1.4 Mice and cell lines 
Table 5: Mice 
Strain Commentary 
BALB/c (H-2
d
) mice Harlan-Winckelmann GmbH, Borchen, Germany 
C3H/HeJ LPS non-responder mice  Jackson Laboratory, USA  
OT-I,  OT-II and DO.11.10 mice 
Bred in animal facility of the Helmholtz Centre for Infection 
Research (HZI) 
 
Type I IFN reporter mice  
(IFN-ß
+/∆ß-luc 
, LycM, CD11ccre, CD4cre, 
CD19cre, IFNAR -/- ) 
 
Bred in animal facility of the HZI 
 
 
Cell lines    
The J774A.1 (mouse monocytes-macrophages) cell line was obtained from the 
DSMZ (German National Resource Centre for Biological Material). The cell line was 
established from a tumour in a female BALB/c mouse in 1968; J774A.1 cells were described 
to synthesize lysozyme and interleukin-1 and to have receptors for Ig and complement. They 
are relatively small cells growing adherently; adherent cells will round up after a few days in 
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culture [115]. The cells were cultured in DMEM with 5% heat-inactivated FCS, 
penicillin/streptomycin, 2 mM glutamine and 2.5 x 10-2 M 2-mercaptoethanol. They were 
incubated at 37°C (5% CO2) in a humidified atmosphere, having a doubling time of 17 hours. 
 
2.1.5 Solution and buffer used for ELISA 
 
Table 6: Solution and buffers for ELISA 
Solutions / buffers Compositions 
Coating buffer Carbonate buffer 
Blocking buffer (ELISA) PBS – BSA 3% (w/v) 
Washing buffer (ELISA) PBS – Tween 0.1% (v/v) 
Dilution buffer PBS-BSA 3% (w/v) 
ABTS/H2O2 solution 0.03% (v/v) H2O2 in ABTS-solution 
 
2.1.6 Solution and buffer used for ELISPOT 
Table 7: Solutions and buffers for ELISPOT 
Solutions / buffers Compositions 
Coating buffer 1 x PBS 
Blocking solution RPMI 1640 medium + 10% FCS + 1% penicillin-streptomycin-L-glutamine 
Wash buffer I 1 x PBS + 0.05% Tween-20 
Wash buffer II 1 x PBS 
Dilution buffer 1 x PBS + 10% FCS 
Substrate solution 
333.3 µl of AEC stock solution (100 mg AEC in 10 ml DMF) +10 ml 0.1 mM acetate 
solution + 5 µl H2O2 
 
2.1.7 Antibodies 
Table 8: Murine surface antibodies used for FACS analysis 
Antibodies/Conjugate Clone Species Dilution Company 
Anti-mouse CD16/CD32 purified 
(FcR-block)  
2.4G2 mouse 1:500 BD Pharmingen
TM
, USA 
Anti-mouse CD3 APC/PE 145-2C11 hamster 1:500/1:200 eBioscience, USA 
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Anti-mouse CD4 APC / PE-Cy7 RM4-5 rat 1:500/1:1,500  eBioscience, USA 
Anti-mouse CD8 APC 53-6.7 rat 1:500 eBioscience, USA 
Anti-mouse CD11b PE / 
eFluor®450 
M1/70 rat 1:300  / 1:800 BD Pharmingen
TM
, USA 
Anti-mouse CD11c PE-Cy7 N418 hamster 1:800 BD Pharmingen
TM
, USA 
Anti-mouse CD25 PE PC61.5 rat 1:300 eBioscience, USA 
Anti-mouse CD40 FITC 3/23 rat 1:100 BD Pharmingen
TM
, USA 
Anti-mouse CD45R (B220) PE-
Cy5 
RA3-6B2 rat 1:300 eBioscience, USA 
Anti-mouse CD54 FITC 
(ICAM-1) 
3E2 hamster 1:100 BD Pharmingen
TM
, USA 
Anti-mouse CD62L FITC 
(L-Selectin) 
MEL-14 rat 1:1,000 eBioscience, USA 
Anti-mouse CD80 APC 
(B7-1) 
16-10A1 hamster 1:1,200 BD Pharmingen
TM
, USA 
Anti-mouse CD86 PE 
 (B7-2) 
GL1 rat 1:500 BD Pharmingen
TM
, USA 
Anti-mouse H-2K
d
 FITC
 
 (MHC-I) 
SF1-1.1 mouse 1:100 eBioscience, USA 
Anti-mouse I-A/I-E eFluor450 
(MHC-II)
 
M5/114.15.2 rat 1:200    eBioscience, USA 
Live/Dead Far Red kit  -------- --------- 1:1,000 Invitrogen 
Anti-mouse CD205 (DEC205)  
PerCP-eFluor 710 
205yekta rat 1:200 eBioscience, USA 
 
 
Table 9: Murine antibodies used for FACS analysis against intracellular targets 
Antibodies/Conjugate Clone Dilution Company 
IL-10 Alexa700 JES5-16E3 1:100  BD Pharmingen
TM
, USA 
IL-12/23p40 Alexa647  C17.8 1:400  eBioscience, USA 
 
 
Table 10: Human antibodies used for FACS analysis 
Monoclonal Antibodies 
[all obtained from mouse] 
Clones Dilution Company 
Anti-human CD11c V450 B-Ly6 0.5 µl/5 x10
5
cells BD Pharmingen
TM
, USA 
Anti-human CD14 PE M5E2 5 µl/5 x 10
5
cells BD Pharmingen
TM
, USA 
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Anti-human CD40 FITC 5C3 1 µl/5 x 10
5
cells BD Pharmingen
TM
, USA 
Anti-human CD54 APC HA58 1 µl/5 x 10
5
cells BD Pharmingen
TM
, USA 
Anti-human CD80 PE L307.4 1:10 BD Pharmingen
TM
, USA 
Anti-human CD83 APC HB15e 1:10 BD Pharmingen
TM
, USA 
Anti-human CD86 PE-Cy5 2331 1:10 BD Pharmingen
TM
, USA 
Anti-human HLA-DR FITC TU36 1:10 BD Pharmingen
TM
, USA 
Anti-human CD19 APC HIB19 0.5 µl/5 x 10
6
cells BD Pharmingen
TM
, USA 
Live/Dead APC-Cy7  1:1000 Invitrogen 
 
 
Table 11: Antibodies used for ELISA 
Antibodies Conjugated Species Dilution Company 
Anti-mouse IgA Purified mouse 
5 µg / ml 
(standard) 
Sigma-Aldrich 
Anti-mouse IgA Purified goat 1:200 Sigma-Aldrich 
Anti-mouse IgG Purified goat 1:200 Sigma-Aldrich 
Anti-mouse IgG1 Purified goat 1:10,000 Sigma-Aldrich 
Anti-mouse IgG2a Purified goat 1:5,000 
SBA (southern 
biotechnology Associates) 
Anti-mouse IgA Biotinylated goat 1:5,000 Sigma-Aldrich 
Anti-mouse IgG Biotinylated goat 1:5,000 Sigma-Aldrich 
Anti-mouse IgG1 Biotinylated goat 1:2,000 SBA 
Anti-mouse IgG2a Biotinylated goat 1:10.000 SBA 
 
 
Table 12: Antibodies used for ELISPOT 
Antibodies Conjugated Species Dilution Company 
Anti-mouse IFN-y Purified rat 1:200 BD Pharmingen
TM
 
Anti-mouse IL-2 Purified rat 1:200 BD Pharmingen
TM
 
Anti-mouse IL-4 Purified rat 1:200 BD Pharmingen
TM
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Anti-mouse IL-17 Purified rat 1:250   BD Pharmingen
TM
 
Anti-mouse IFN-y Biotinylated rat 1:250 BD Pharmingen
TM
 
Anti-mouse IL-2 Biotinylated rat 1:250 BD Pharmingen
TM
 
Anti-mouse IL-4 Biotinylated rat 1:250 BD Pharmingen
TM
 
Anti-mouse IL-17 Biotinylated rat 1:250   BD Pharmingen
TM
 
 
2.1.8 Adjuvants 
Table 13: Adjuvants 
Adjuvants Commentary: 
c-di-AMP  Synthesized by Dr. Morr, HZI, dissolved in Ampuwa®, stored at –20°C 
c-di-GMP Synthesized by Dr. Morr, HZI, dissolved in Ampuwa®, stored at –20°C 
c-di-IMP Synthesized by Dr. Morr, HZI, dissolved in Ampuwa®, stored at –20°C 
 
2.1.9 Synthesis of cyclic di-nucleotides 
The c-di-GMP and c-di-AMP were synthesized by crystallization according to 
established protocols [98, 116]. The resulting compound was purified by reversed-phase 
high-performance liquid chromatography at RT using a Phenomex column (50 by 2 mm, 4 
μm, C18) and a gradient of 25 mM triethylammonium formic acid (solvent A [pH 6.8]) to 
acetonitrile (solvent B) from 0% to 20% solvent B within 20 min at a flow rate of 0.7 ml/min. 
Subsequently, the sodium form of c-di-GMP was obtained by Dowex-Na+ ion exchange. The 
structure of water-soluble c-di-GMP and c-di-AMP was confirmed by 1H- und 13P-nuclear 
magnetic resonance and matrix-assisted laser desorption-ionization mass spectrometry.  In 
order to assess if structural related compounds also exert adjuvant activity, bis-(3‟,5‟)-cyclic 
dimeric inosine monophosphate (c-di-IMP) was synthesized out of the parenteral compound 
c-di-AMP through adenosine-deamination. The final lyophilized compound was stored at -
20°C. For the immunization studies, c-di-GMP, c-di-AMP and c-di-IMP were dissolved in 
sterile water. The cyclic di-nucleotide solution was stable for at least six months at -20°C and 
two months at 4°C. 
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2.2 METHODS 
2.2.1 Properties of cyclic di-nucleotides 
 
2.2.1.1 HEK BlueTM LPS detection 
  The HEK-BlueTM cells were thawed under gently agitation in a 37°C water bath and 
transferred in a sterile tube containing 15 ml of growth medium, DMEM high glucose (4.5 g/L) 
supplemented with 10% FCS, penicillin-streptomycin and 1 x NormocinTM , and spin at 1,500 
x g for 5 min. After removing the supernatant containing the cryoprotective agent, cells were 
re-suspended with 1 ml of the growth medium. The contents of the vial were transferred to a 
25 cm2 tissue culture flask containing 5 ml of growth medium. The flask was incubated at 
37°C (5% CO2) in a humidified atmosphere until 50–80% confluency was reached. The cells 
were then trypsinized and cultivated into growth medium supplemented with 1x HEK-BlueTM 
Selection. Cells were passaged 2 to 3 times a week until 60–80% of confluency was reached 
and diluted with pre-warmed HEK-BlueTM detection medium at a concentration of 1 x 105 
cells/ml. First, to a 96-well sterile flat-bottomed cell culture plate were added 20 μl/well of 
different dilutions from each sample (1:10, 1:20, 1:40 and 1:80), and 20 μl/well of endotoxin-
free water as a negative control. As positive control, 20 μl/well of E. coli K12 LPS in serial 
dilutions of 0.1, 0.3, 1, 10 and 100 ng/ml were added. Afterwards, 200 μl/well of the cell 
suspension were loaded and plates were incubated at 37°C (5 % CO2) in a humidified 
atmosphere for 18 to 24 h. HEK-Blue™-4 cells stably express an optimized alkaline 
phosphatase gene engineered to be secreted, which is placed under the control of a 
promoter inducible by several transcription factors such NF-κB. Therefore, the HEK-BlueTM 
Detection medium turns into a blue colour in the presence of phosphatase activity and can 
be quantified after the specified incubation time by spectrophotometric measurement at 620-
655 nm or with the naked eye by comparing with the positive control which appear in blue 
and the negative control should be pink or light purple.  
 
2.2.1.2 Nitric Oxide release assay 
  Activated murine macrophages synthesize nitric oxide (NO), which resolves into 
nitrate and nitrite. Nitrate is enzymatically transformed into nitrite and can then be detected 
as an Azo-dye. The amount of NO gives information about the biological activity of the 
stimulated macrophages. The nitric oxide release assay was performed as previously 
described [117, 118]. In brief, female C3H/HeJ LPS non-responder mice (Jackson 
Laboratory, USA) were used at the age of 10 to 18 weeks. Resident murine peritoneal 
exudate cells were exploited as a source of peritoneal macrophages. To this end, mice were 
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asphyxiated with CO2 immediately before injection of about 3 ml of ice-cold PBS with 1% 
FCS into the peritoneal cavity. After gently massages of the abdomen, the cells were 
withdrawn, centrifuged at 4°C, and adjust to 2 x 106 cells per ml in DMEM supplemented with 
5% FCS, 2 mM L-glutamine and 25 mM 2-mercaptoethanol. Recombinant murine IFN-y 
(62.5 U/ml) was added to the cells and 50 μl of the cell suspension was added to 50 μl of 
serial 1:2 diluted adjuvants in medium, in 96-well flat-bottomed microtiter plates. After 45 h 
incubation at 37°C in a humidified atmosphere with 5% CO2, 10 μl of a solution containing 
nitrite reductase from Aspergillus spp (Boehringer # 981 249; 20 U lyophilized) and NADPH 
trinatrium (Boehringer # 107 824) (equals 8.18:1) was added mixed well and incubated for 10 
min. Then 100 μl/well of Griss reagent, consists of a freshly made 1:1 mixture of 0.1% 
naphthylethylendiamine- 2·HCl in water and 1% sulphanilamide in 5% H3PO4, was added for 
10 min. As golden standard R-MALP-2 (approximately 0.2 ng/ml) and LPS (approximately 
0.1 μg/ml) were used (data not shown). The NO-value was analysed with the 
spectrophotometer plate reader (ELISA Reader) at 550 nm vs. 690 nm. 
 
2.2.2 Evaluation of the adjuvanticity of c-di-AMP  
2.2.2.1 Intranasal vaccination with c-di-AMP as adjuvant 
For intranasally (i.n.) immunization mice were individually anaesthetized by inhalation 
of Isofluoran® Curamed (Essex Tierarznei, Germany). A maximum of 10 μl of vaccine 
formulation per nostril were slowly administered by holding the mouse headlong and waiting 
until the liquid was completely absorbed. By administrating this small volume it was ensured 
that the whole dose remains in the nasal mucosa, minimizing the risk that it reaches the 
lungs or is swallowed. Groups of 3-5 six-weeks-old BALB/c mice were immunized i.n. on 
days 0, 14 and 28 with 15 μg of ß-Gal or OVA alone or co-administered with 5 µg/dose of c-
di-AMP. Mice of the positive control group were vaccinated using CTB as adjuvant. Animals 
of the negative control group received PBS or Ampuwa. Fourteen days after the last boost 
animals were sacrificed by CO2 inhalation and sera, nasal washes, lung and vaginal lavages, 
as well as the bone marrow, cervical lymph nodes and spleen were recovered from the mice 
to analyse humoral and cellular immune responses (Figure 4). 
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Figure 4: Overview of the immunization protocol 
 
 
2.2.2.2 Health Control 
To control the health of immunized mice and to check for the occurrence of side 
effects (e.g. fever), the optical appearance, the behaviour and the weight of the individual 
animals were controlled before first immunization and two, four and six days after the 
immunization and each booster (day 14 and 28). 
 
2.2.2.3 Sampling of mice 
Sera 
To monitor humoral immune responses, the presence of antigen-specific IgG in sera 
of immunized mice was analysed. During an immunization experiment individual blood 
samples were taken before the first immunization (day -1), the second immunization (1st 
boost, day 12), the third immunization (2nd boost, day 26) and 14 days after the last 
vaccination dose. Blood samples were taken via the retro-orbital plexus by using 40 μl glass 
capillaries. Serum was obtained by allowing the blood to coagulate during 1 h (incubation at 
37°C), followed by 30 min incubation at 4°C. To separate the serum from other blood 
components, the tubes were centrifuged at 7,000 x g in a table centrifuge for 10 min at room 
temperature (RT). Then, supernatants were carefully removed and stored at –20°C (until 
ELISA). 
 
Euthanasia of mice 
   To sample spleens, NALT, lymph nodes (LN), bone marrow derived DCs and 
vaginal lavages the mice were sacrificed by cervical dislocation. When the mucosal immune 
responses of the lungs or noses were examined, mice were euthanized by CO2 inhalation 
instead of cervical dislocation in order to prevent blood from flooding to the lungs and mixing 
with the secretions of the mucosal membranes. 
 
 
Day
13 14 27 28 420 1
= Immunization/Boost= Sera = Sampling
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Collection of Spleen 
To prevent contamination the mouse was soaked with 70% ethanol. The abdomen 
was carefully disembowelled and by using tweezers and scissors the spleen was removed 
and stored in RPMI complete on ice. Spleens of immunized mice were pooled for each 
group. 
 
Nasal Lavage 
   To detect secretory IgA in the nasal cavities following i.n. immunization, the lower 
jaw was cut and a 200 μl tip was inserted into the posterior opening of the nasopharynx. 
Nasal cavities were then flushed twice with 200 μl of lavage buffer (5% FCS/1xPBS), which 
was collected in a 1.5 ml tube with 10 μl of 40 mM PMSF. The collected probes were 
centrifuged at 7,000 x g in a table centrifuge for 10 min at RT The supernatant was carefully 
removed and stored at –20°C until the IgA ELISA was performed. 
 
Lung Lavage 
   To analyse the stimulation of secretory IgA in the lung after immunization, individual 
lung lavages of each mouse were obtained. The neck skin and muscles were carefully 
removed with tweezers and a small cut was set in the middle of the trachea between two 
rings without intersecting the whole trachea using scissors. A catheter of 1 mm diameter was 
carefully inserted into the lung. Via a 1 ml syringe 1,000 μl of lavage buffer (5% FCS/1xPBS) 
were injected and the ribcage was massaged to get the secretory components. Then, the 
buffer was withdrawn and collected in a 1.5 ml tube with 10 μl of 40 mM PMSF. The collected 
probes were centrifuged at 7,000 x g in a table centrifuge for 10 min at RT The supernatant 
was carefully removed and stored at –20°C until the IgA ELISA was performed. 
 
Vaginal Lavage 
   To investigate secretory IgA production after immunization in the genital tract, 
individual vaginal lavages were taken from each mouse. To this end, the mucosa of the 
vagina was flushed two times with 500 μl of lavage buffer (5% FCS/1xPBS) by carefully 
inserting a 1,000 μl tip into the vagina. After pipetting several times up and down, the lavage 
probes were collected in a 1.5 ml tube with 10 μl of 40 mM PMSF for preventing the 
degradation of proteins. Then, the probes were centrifuged at 7,000 x g for 10 minutes at RT 
to remove the debris. Finally, the supernatant was carefully taken off and collected in a 1.5 
ml tube filled with 10 μl of 40 mM PMSF and stored at –20°C for determination of IgA by 
ELISA. 
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2.2.2.4 Preparation of single cell suspension of spleen, cLN, NALT and BM 
Spleen 
   To obtain a single cell suspension of the spleens and cervical lymph nodes (cLN), 
the organs were mechanically dissociated in RPMI complete by gently pressing them through 
a 100 μm cell mesh using the rubber cap of a 2 ml syringe plunger. The cell suspension was 
transferred to a 50 ml Falcon tube and centrifuged at 300 x g for 10 min at RT. For the 
depletion of the erythrocytes the pellet was re-suspended in ACK lysis buffer (3 ml/spleen). 
After 60 seconds the tube was filled with RPMI complete to stop the lysis. The cell 
suspension was centrifuged as described above, the pellet was re-suspended in RPMI 
complete (4 ml/spleen) and filtered through a 100 μm mesh to remove the released DNA 
fragments and cell debris. The number of cells was then determined by using the Neubauer 
cell counter chamber or the cell counter Z2 from Beckman-Coulter and adjusted to 5 x 106 
cells/ml. Cells which were not immediately needed, were re-suspended in freezing medium 
(10% DMSO in FCS) at a concentration of 108 cells/ml and transferred into cryotubes. To 
achieve the recommended cooling of 1°C/min the cells were retained for 24 h at -70°C in 
Nalgene® Cryoboxes boxes filled with isopropanol. After 24 h the cells were stored at -196°C 
in the liquid phase of a nitrogen tank until further usage. 
 
NALT 
   For the isolation of APCs in the NALT 24 h after intranasal administration of c-di-
AMP, the lower jaw and tongues were removed, then the upper palate was removed with 
scalpel and tweezers, and NALT were taken and transferred onto a Petri dish containing 
RPMI-complete medium. Cells were scratched from the nasal cavity walls and single-cell 
suspensions were prepared by mincing the tissue through a 100 μm nylon mesh. Cells were 
washed twice with RPMI complete medium at 300 x g, for 10 min at RT and then prepared 
for flow cytometry staining, as described above. 
 
cLN 
Following i.n. immunization cervical draining lymph nodes were collected in RPMI 
complete medium and prepared in the same way as described above for splenocytes. 
Afterwards, cells were used for APC flow cytometric analysis. 
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2.2.2.5 Detection of cell number 
   The cell number can be determined using either the Neubauer cell counter chamber 
(haemocytometer) or the electronic cell counter Z2 (Beckman-Coulter). For counting cells in 
the Neubauer counting cell chamber, the cell suspensions are diluted in Trypan blue solution, 
added into the haemocytometer chamber and enumerated under the light microscope. 
Trypan Blue is excluded from living cells, whereas dead cells showed an enhanced uptake of 
the blue coloured dye. Depending on the concentration, the cell suspension was mixed with 
Trypan blue solution to reach a final dilution (y), which allows counting of the cells. The cells 
were filled into the chamber of the haemocytometer and the non-stained, i.e. viable, and 
dead cell cells were enumerated by using a microscope. After counting the cells in the 4 big 
squares, each consisting of sixteen small quadrates, the cell number per ml was determined 
by the following formula: 
 
Total cell number = (counted cells / 4 squares) x dilution (y) x 104 
 
The other possibility to determine the cell number is the usage of the electronic cell counter 
Z2. The method of sizing and counting particles with the electronic cell counter is based on 
measurable changes in electrical resistance produced by non-conductive particles 
suspended in an electrolyte. In the sensing zone, i.e. a small opening between electrodes, 
each passing particle displaces its own volume of electrolyte which is measured as a voltage 
pulse; the height of each pulse being proportional to the volume of the particle. The 
Beckman-Coulter counter reports both count and concentration and provides the possibility 
to display the size distribution of the cell population. In comparison to the Neubauer counting 
cell chamber, dead and living cells cannot be distinguished in one step. To determine the cell 
number using the electronic counter, the cell suspension was diluted 1:500 in Isotone II, a 
near physiological saline solution. Spleen cells were measured at a size between 5 μm and 
16 μm of diameter by using the Multi32 Coulter Z2® AccuComp® v3.01 software (Beckman-
Coulter). 
 
2.2.2.6 Detection of antigen-specific antibodies by ELISA 
Antigen-specific IgG 
   ß-Gal- and OVA-specific antibodies were determined in serum samples by ELISA 
using microtitre plates coated with 100 µl/well of the respective antigen (5 µg/ml in 0.05 M 
carbonate buffer (pH 9.6), as previously described [119]. After overnight incubation at 4°C, 
plates were blocked with 3% BSA in PBS for 1 h at 37 °C. Serial 2-fold dilutions of sera in 3% 
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BSA/1xPBS were added (100 µl/well), and plates were further incubated for 2 h at 37 °C. 
After six washes with 1% BSA/1xPBS/0.05% Tween 20, secondary antibodies were added 
(see Table 11), such as biotinylated y-chain-specific goat anti-mouse IgG or for the 
determination of the different IgG subclasses, biotinylated goat anti-mouse IgG1 and IgG2a 
(Sigma, USA) for BALB/c mice. Subsequently, the samples were incubated at 37°C for 2 h 
[119]. After six washing steps, 100 µl of peroxidase-conjugated streptavidine (BD 
Pharmingen, USA) was added to each well, and plates were incubated at RT for 1 h. After 
another six washes, reactions were developed using ABTS in 0.1 M citrate–phosphate buffer 
(pH 4.35) containing 0.01% H2O2. Endpoint titres were expressed as absolute values of the 
last dilution which gave an optical density at 405 nm of 2 times above the values of the 
negative controls after 15 and 30 min of incubation. 
 
Antigen-specific IgM, IgA and SC in mucosal secretions 
   The amount of antigen-specific secretory antibodies IgM, IgA and SC present in the lavage 
samples of nasal cavity, lung and vagina was determined by ELISA, as previously described 
[119]. Briefly, 96-well microtitre plates were coated overnight at 4°C with 100 µl/well of ß-Gal 
or OVA at a concentration of 2 µg/ml diluted in carbonate buffer. After blocking with 3% 
BSA/PBS for 1 h at 37 °C, the plates were washed and further incubated with 2-fold serial 
diluted lavages samples (starting with 1:4) for 1 h at 37°C. After four washes, anti-mouse IgA 
or IgM biotinylated detection antibodies (Sigma, USA) were added in each well. The plates 
were further incubated for 1 h at 37°C. After the plates were washed, peroxidase-conjugated 
streptavidine (BD Pharmingen, USA) was added and the plates were incubated at RT for 1 h. 
The plates were washed and reactions were developed using ABTS in 0.1 M citrate–
phosphate buffer (pH 4.35) containing 0.01% H2O2. For the detection of the SC, plates 
coated with ß-Gal were blocked with 5% of normal donkey serum (v/v) for 2 h. Serial dilutions 
of the lavage samples were incubated (1 h) and subsequently washed. The antibodies 
containing the SC were detected by 1 h incubation with a 1:200 dilution of a goat anti-pIgR 
(R&D Systems; USA). For the detection, plates were further incubated with a 1:10,000 
dilution of HRP-conjugated donkey anti-goat IgG (Jackson ImmunoResearch, USA) followed 
by development with ABTS diluted in 0.1M citrate–phosphate buffer (pH 4.35) containing 
0.01% H2O2. Results were expressed as endpoint titres of the last dilution which gave an 
optical density at 405 nm of two times above the values of the blank after 30 min of 
incubation. 
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2.2.2.7 Enzym-Linked Immunospot Assay (ELISPOT)   
   ELISPOT assays were performed using flat bottomed 96-well plates with a 0.45 µm 
hydrophobic High Protein Binding Immobilin-P-Membran. The plates were coated with 100 
µl/well of the corresponding capture antibody (anti-IFN-γ, anti-IL-2, anti-IL-4 or anti-IL-17), 
diluted 1:200 in PBS and stored overnight at 4°C. To remove unbound capture antibody, the 
plate was washed once with 200 µl/well of blocking solution (RPMI complete medium). Then, 
the unspecific binding sites were saturated by incubating with 200 µl/well of blocking solution 
for 2 h at RT. Afterwards, 200 µl/well corresponding to 1 x 106 cells/well of single spleen cell 
suspensions were added in triplicates to the plate. To analyse IFN-γ secretion, the spleen 
cells were re-stimulated by adding 50 µl/well of the CD8+-specific β-Gal peptide diluted in 
RPMI complete medium to reach a final concentration of 5 µg/ml. The cells used for 
detection IL-2, IL-4 or IL-17 secretion were co-cultured with 5 µg/ml of β-Gal. As negative 
control, cells were cultured in RPMI complete medium without stimulants. As positive control, 
ConA diluted in RPMI complete medium (final concentration 5 µg/ml) was used to stimulate 1 
x 106 cells/well. The plates were incubated at 37°C and 5% CO2 for 24 or 48 h to detect IFN-
γ or IL-2, IL-4 and IL-17 secretion, respectively. After the incubation, the cell suspension was 
aspirated and the plates were washed twice with deionized water including a soaking for 5 
min followed by three washes using 200 µl/well of wash buffer (0.05 % Tween-20/PBS). To 
detect the captured cytokines, 100 µl/well of the corresponding biotinylated detection 
antibody diluted 1:250 in dilution buffer (10% FCS/PBS) was added and incubated for 2 h at 
RT. After washing three times with 200 µl/well of wash buffer, 100 µl/well of avidin HRP 
diluted 1:100 in dilution buffer were incubated for 1 h at RT. The plates were then washed 
four times with 200 µl/well of wash buffer and subsequently twice with PBS. Spots were 
developed for 5 to 60 min using 100 µl/well of substrate solution (333.3 µl of AEC stock 
solution + 10 ml of 0.1 mM acetate solution + 5 µl H2O2). The reaction was stopped by 
washing the plate with deionized water. After drying the plates for 2 h at RT in the dark, the 
plates were scanned with an ImmunoSpot series 3A analyzer and spots were counted by 
using the ImmunoSpot image analyzer software (version 3.2; Cellular Technology, Ltd.). The 
results were expressed as spot forming units (SPU) for 1 x 106 spleen cells/well. The spots 
produced by the non re-stimulated cells served as background and were subtracted from the 
spots produced by the re-stimulated cells. Antibodies used for ELISPOT are listed in Table 
12. 
 
2.2.2.8 Determination of lymphoid-mediated cytotoxicity in vivo 
   To investigate the influence of c-di-AMP on the stimulation of antigen-specific CTLs, 
splenocytes obtained from naïve C57BL/6 mice were washed twice with serum-free RPMI 
   
  MATERIALS AND METHODS 
 
42 
 
medium at 200 x g for 10 min at RT and split into two equal proportions, each at a 
concentration of 1 x 107 cells/ml. One aliquot was labelled with a high concentration of CFSE 
(1 μM), whereas the other one was labelled with a low concentrated CFSE (0.1 μM). The 
labelled splenocytes were incubated for 7 min at 37°C and 5% CO2 in the dark. The labelling 
was interrupted by adding an equal volume of medium containing 5% FCS for 10 min at 37°C 
and 5% CO2. Afterwards, the cells were washed twice with RPMI complete medium and the 
high CFSE labelled spleen cells were pulsed with the OVA peptide (amino acids 257 to 264) 
at a concentration of 15 μg/ml for 1 h at 37°C and 5% CO2. The low CFSE labelled cells were 
incubated without peptide stimulation. After 1 h cells were washed twice and an equal 
number of cells deriving from each type of labelling were mixed. A total of 2 x 107 cells were 
injected intravenously into mice immunized by parenteral or mucosal route with OVA (50 
μg/mouse) co-administered with 5 μg c-di-AMP two weeks after last vaccination (day 1, 14, 
28). After 16 h, spleens were collected and analysed by flow cytometry. Specific lysis was 
determined by the decrease of CFSE of the peptide pulsed population in comparison with the 
non-stimulated cells. The following formula was used to calculate the percentage of OVA-
specific lysis: 
 
100 – (% CFSEhigh in immunized mice / % CFSElow in immunized mice) 
(% CFSEhigh in control mice / % CFSElow in control mice) 
 
 
2.2.2.9 T cell proliferation assay 
  The ability of T cells to proliferate after efficient stimulation can be determined by 
measuring the uptake of radioactive [3H]-thymidine, which is building in the DNA. To 
determine the proliferative capacity of spleen cells, single spleen cell suspensions of 
immunized mice were prepared as described above, adjusted to 5 x 106 per ml in RPMI 
complete medium and 100 μl/well were seeded in a 96-well sterile flat-bottom cell culture 
plate. For the re-stimulation of spleen cells, 100 ml/well of β-Gal diluted in RPMI-complete 
medium were added in quadruplicates (final concentration of 40, 20, 10, 5 and 1 μg/ml). As 
positive control, the mitogen concavalin A (ConA) was used at the final concentration of 5 
μg/ml, whereas the negative controls received medium alone. The plates were incubated at 
37°C and 5% CO2 in a humidified atmosphere. After four days of incubation, splenocytes 
were pulsed with 50 ml/well of [3H]-thymidine diluted in RPMI-complete medium (1 μCi/well) 
during the final 16-18 h of culture. Then, cells were harvested on glass fibre filters by using a 
cell harvester (InoTech). After drying the filter in a microwave, the scintillator sheet was melt 
on the filter. This transfer of [3H] thymidine into the wax layer, which constitutes a kind of 
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scintillation fluid, allows the final measuring of the radioactivity using the gamma-scintillation 
counter (1450 Microbeta, Wallach Trilux). Results were expressed as the arithmetic mean of 
[3H]-thymidine uptake in counts per minute (cpm) or as stimulation indexes, being the ratio of 
[3H]-thymidine uptake of stimulated versus non-stimulated samples. 
 
2.2.2.10 Stimulation of cytokine secreting cells 
   Cytokines secreted by re-stimulated immune cells exert effector functions on 
immune cells, thereby affecting the outcome of both cellular and humoral immune responses. 
This depends on the type of cytokines which are produced by the specific Th subset (e.g. 
Th1, Th2). Thus, to investigate the type and amount of cytokines secreted from re-stimulated 
spleen cells of immunized mice, spleen single cell suspensions were in vitro re-stimulated 
using different ß-Gal concentrations according to the T cell proliferation assay. Briefly, 5 x 
105 spleen cells were incubated in quadruplicates, with or without ß-Gal (40, 20, 10, 5 and 1 
μg/ml final concentration) in a total volume of 200 μl for 96 h at 37°C and 5% CO2. Positive 
control cells were stimulated with ConA (5 μg/ml). After centrifugation for 5 min at 300 x g at 
RT, the supernatant was carefully aspirated and stored at -70°C until the secreted cytokines 
were analysed by different cytokine array assays. For quantification, the contents of IL-6, IL-
10, IL-17 and IFN-γ in the collected supernatants were determined using a Mouse Th1/Th2 
10plex FlowCytomix cytokine array according to the manufacturer's instructions 
(eBioscience, Bender MedSytems®, USA). Supplied standards were used to generate 
standard curves.  
 
2.2.3 Examination of the immune effector functions of c-di-AMP on murine 
immune cells 
 
2.2.3.1 Generation of bone-marrow derived dendritic cells (BMDCs)  
   Ten to twelve weeks old BALB/c mice were killed and carefully sprayed with ethanol 
70% to prevent contaminations. After removing the skin and muscles using a pair of scissors, 
the hind legs were disconnected from the body in front of the hip. The feet were cut off and 
the intact femurs and tibias were put in a Petri dish with ethanol 70% for 2 to 5 min for 
disinfection. Then, the bones were transferred in a Petri dish with DC medium and stored on 
ice. To obtain the bone marrow, the bones were flushed with medium using a 1 ml syringe 
and a 26G x ½ needle and collected in a tube. The end of the bones and the flushed bones 
were disrupted and crushed with a strong pair of scissors. The pellet was re-suspended in 
ACK buffer (5 ml for the bone marrow of 10 mice) to remove the erythrocytes. The lysis was 
stopped after 2 min by adding 20 ml of DC medium and after centrifugation for 10 min at 300 
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x g at RT the cells were re-suspended in DC medium. Finally the cells were filtrated through 
a 100 m mesh to remove released DNA fragments and pieces of fat. The cells were 
adjusted to 1 x 107 cells/ml in DC medium, seeded onto a 10 cm diameter cell culture dish 
with 10 ml/dish, and incubated at 37°C (5 % CO2) in a humidified atmosphere for 1-2 h to 
remove adherent cells like macrophages. The non-adherent cells were collected and 
centrifuged for 10 min at 300 x g at RT. The pellet was re-suspended in DC medium 
supplemented with either 5 ng/ml cytokine GM-CSF or 100 ng/ml FMS-like tyrosine kinase 3 
ligand (Flt3L), for obtaining differentiated DCs, respectively. The cells were adjusted to a 
concentration of 1 x 106 cells/ml, seeded in 6-well-plates at 5 ml/well and incubated for at 
37°C (5% CO2) in a humidified atmosphere. After 3 days, 1 ml of the supernatant was 
carefully aspirated from each well and replaced with fresh GM-CSF supplemented DC 
medium. The GM-CSF stimulated DCs were used on day 5 or 6, whereas the Flt3L 
stimulated DCs were used on day 9 or 10 for in vitro stimulation with adjuvants. 
 
2.2.3.2 Generation of murine bone-marrow derived macrophages (MΦs) 
 To generate bone marrow-derived primary macrophages (MΦs) from C57BL/6 or 
BALB/c mice, femur and tibia of mice were flushed with medium, as described above. 
Erythrocytes were lysed by adding ACK buffer. Finally the cells were filtrated through a 100 
m mesh to remove released DNA fragments and pieces of fat. The cells were adjusted to 
1x107 cells/ml in MΦ medium supplemented with M-CSF, seeded onto a 10 cm diameter cell 
culture dish with 10 ml/dish, and incubated at 37°C (5 % CO2) in a humidified atmosphere. 
Every 2-3 days the cell culture dishes were washed twice with cold PBS and fresh MΦ media 
was added. After 7-9 days the MΦs were detached with a rubber policeman by careful 
scratching the surface of the Petri dishes, and used for in vitro stimulation with adjuvants. 
 
2.2.3.3 In vitro stimulation of DCs and MΦs with c-di-AMP  
To analyse the effect of adjuvants on the maturation and activation of murine DCs 
and MΦs, cells were stimulated in vitro with c-di-AMP or LPS. From each well, 1 ml of 
supernatant was carefully aspirated and substituted with fresh DC or MΦ medium 
supplemented with GM-CSF or M-CSF and the corresponding stimulants. The adjuvant was 
used at final concentration of 1 g/ml for DCs and MΦs. As positive control, LPS, a well-
known stimulator of DCs and MΦs [120], was used at a final concentration of 1 g/ml. Non-
stimulated DCs or MΦs were used as negative control. The cells were incubated for 24 h at 
37°C (5% CO2) in a humidified atmosphere, then, they were collected in a tube and 
centrifuged at 300 x g for 10 min at RT. To investigate adjuvant induced changes in murine 
   
  MATERIALS AND METHODS 
 
45 
 
DC and MΦ maturation and activation, the expression of the phenotypic markers CD40, 
CD54, CD80, CD86, and MHC class I and II (Table 8) was evaluated by flow cytometry. 
 
2.2.3.4 Isolation and stimulation of murine B cells 
To analyse the effect of c-di-AMP on the activation of murine B cells in vitro, 
splenocytes taken from 6-8 weeks old BALB/c mice were isolated as described before. For 
the depletion of the erythrocytes the pellet was re-suspended in ACK lysis buffer (3 
ml/spleen). After 60 seconds the tube was filled with RPMI complete to stop the lysis. The 
cell suspension was centrifuged as described above, the pellet was re-suspended in RPMI 
complete (4 ml/spleen) and filtered through a 100 μm mesh to remove the released DNA 
fragments and cell debris. The number of cells was determined by using the cell counter Z2 
from Beckman-Coulter. Then, cells were stained with for the B cell marker CD19 for 30 min 
at 4°C and afterwards washed with 1x PBS and adjusted to 2 x 107 cells/ml and sorted for 
CD19+ cells (purity of 98%). To investigate the activation of B cells induced by the adjuvant, 
stimulated cells were stained for the markers CD40, CD80, CD86, and MHC class II (Table 
8) and further analysed by flow cytometry.  
 
2.2.3.5 B cell proliferation assay 
To determine the proliferative capacity of B cells, CD19 sorted B cells were stimulated 
with the adjuvants as described above, adjusted to 5 x 106 per ml in RPMI complete medium 
and 100 μl/well were seeded in a 96-well sterile flat-bottom cell culture plate. As positive 
control, ConA was used at the final concentration of 5 μg/ml, whereas the negative controls 
received medium alone. The plates were incubated at 37°C and 5% CO2 in a humidified 
atmosphere. After four days of incubation, splenocytes were pulsed with 50 ml/well of [3H] 
thymidine diluted in RPMI-complete medium (1 μCi/well) during the final 16-18 h of culture. 
Then, cells were harvested on glass fibre filters by using a cell harvester (InoTech). After 
drying the filter in a microwave, the scintillator sheet was melt on the filter. This transfer of 
[3H] thymidine into the wax layer, which constitutes the scintillation media, allows the final 
measuring of the radioactivity using the gamma-scintillation counter (1450 Microbeta, 
Wallach Trilux). Results were expressed as the arithmetic mean of [3H] thymidine uptake in 
counts per minute (cpm) or as stimulation indexes, being the ratio of [3H] thymidine uptake of 
stimulated versus non-stimulated samples.  
 
 
 
   
  MATERIALS AND METHODS 
 
46 
 
2.2.3.6 Measurement of cellular proliferation of antigen specific murine CD4+ and CD8+ T 
cells  
 
Differentiated murine DCs were incubated with 10 µg/ml of LPS-free OVA 
(EndoGrade® Ovalbumin, #321001, Hyglos, Germany) and 1 µg/ml c-di-AMP or LPS. The 
following day, CD8+ T cells from spleens of OT-I mice, which have a transgenic T cell 
receptor specific for the OVA immunodominant peptide (aa 257-264, SIINFEKL) presented in 
the context of the MHC class I H-2Kb, or CD4+ T cells derived from spleen of OT-II mice 
expressing the TCR specific for OVA (aa 323–339, ISQAVHAAHAEINEAGR) presented in 
the MHC class II molecule I-Ab were isolated. Afterwards, the spleen cells were negatively 
selected by magnetic bead separation (Miltenyi Biotec, Germany), stained with 10 µM CFSE 
(Molecular Probes, USA) in PBS for 5 min and co-cultured with antigen stimulated DCs for 4 
days. The percentages of vital CFSE+ labelled CD8+ and CD4+ cells were then determined by 
flow cytometry on a BD LSRII and analyzed using the BD FACSDiva software. 
 
2.2.3.7 Flow cytometric analysis of murine cells 
Surface staining  
To investigate cell surface markers by flow cytometry, the cells were stained with 
fluorescence labelled antibodies. Every step was performed on ice to prevent the 
internalization of surface molecules or the degradation of cells. The different washing steps 
were important to stabilize the physiologic milieu of the cells. The cell suspensions were 
adjusted to 5 x 106 cells/ml and added in 100 l/well to a 96-well round bottom microtiter 
plate. Cells were washed by centrifugation at 200 x g for 5 min at 4°C. Afterwards, 
supernatants were discarded and cell pellets were re-suspended in 50 μl of FACS buffer 
containing FcR-block diluted 1:2,000. Plates were incubated for 20-30 min on ice. 
Subsequently, cells were centrifuged and after discarding the supernatant, fluorochrome-
labelled antibodies diluted in FACS buffer at the indicated concentrations were added to the 
appropriate wells in a final volume of 50 µl/well (Table 8). In addition, to each staining 
combination a fixable live/dead cell marker was added to exclude dead cells. After 30 min of 
incubation on ice in the dark, cells were washed with 100 µl/well of FACS buffer and the plate 
was centrifuged for 10 min at 200 x g. To fix and stabilize the cells, cell pellets were re-
suspended in 200 µl PBS containing 4% PFA, transferred to a FACS tube and stored on ice 
in the dark until analysis by FACS LSRII (BD Bioscience, USA). To prevent false positive 
signals when dyes were used with overlapping emission spectra, single staining for each 
used antibody was performed for later compensation purposes during data analysis. 
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Intracellular staining  
 Following surface staining, cells were permeabilized with 100 μl/well of 
Cytofix/Cytoperm (BD Bioscience), re-suspended and incubated for 10 min at 4°C. 
Afterwards, cells were washed twice with 100 μl/well Perm wash buffer (diluted 1:10 in water) 
and centrifuged at 200 x g for 5 min at 4°C. Then, the supernatants were discarded and cells 
were stained with the appropriate antibodies (Table 9) diluted in Perm wash buffer at a final 
volume of 50 μl/well. After 20 min of incubation at 4°C in the dark, cells were washed twice 
with Perm wash buffer, re-suspended in 200 μl PBS and stored at 4°C in the dark until 
analysis.  
 
2.2.3.8 Evaluation of APC activation ex vivo  
   To study the in vivo effector functions on innate immune cells of the adjuvant, 
Balb/c mice received c-di-AMP at a concentration of 5 μg per mouse by i.n. route. Control 
mice were treated with either PBS or MALP-2 (0.5 µg/dose) as well-known TLR2/6 agonist 
[118]. After 24 h cells from spleen, NALT and cLN were collected and prepared for each 
mouse separately, as described above. Afterwards, the obtained cell suspensions were 
analysed in terms of surface markers predicting for APC and DCs subset activation and 
functionality by flow cytometry. The used antibodies are listed in Table 8. The staining 
procedures were performed as described above. 
 
2.2.3.9 Electron microscopy analysis of Nanogold-labelled c-di-AMP   
  The Mono-Sulfo-NHS-NANOGOLD® (1.4 nm mean diameter; Nanoprobes, Stony 
Brook, NY) reagent (6 nmol) was dissolved in 200 µl deionized water by extensive vortexing. 
A 20-fold excess of the adjuvant c-di-AMP were used for labelling and incubated 12–18 h 
(overnight). The Nanogold-c-di-AMP conjugate was then given to 6 days old bone-marrow 
derived dendritic cells (BMDCs) and incubated for different time points (0.5 min, 5 min, 30 
min, 2 h, and 6 h) at a humified atmosphere. Cells were fixed in 1% (v/v) glutaraldehyde (GA) 
for 15 min at RT. Afterward, they were centrifuged for 5 min at 300 x g, the supernatant was 
discard and cells were re-suspend in 1 ml of 1 x PBS. The washing step was repeated two 
times.     
 
Fixation and embedding 
Samples from BMDCs were immediately fixed at RT in 2.5% (v/v) GA in 20 mmol L-1 
HEPES buffer (pH 7.1) for 30 min. Cells were stored until embedment for several days at 
4°C. For ultrastructural analysis, cells were immobilized in 2% (w/v) agar. Cells were 
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dehydrated on ice in an ethanol series, stained with 1% (w/v) uranyl acetate in 70% (v/v) 
ethanol and finally infiltrated with epoxy resin [121]. Cells were polymerized at 70°C for 8 h. 
Ultrathin sections (70 nm) were cut with a diamond knife using an ultramicrotome (Leica, 
Wien, Austria), picked with Formvar-coated 300 mesh copper grids and post-stained with 
uranyl acetate and lead citrate, as described previously [122]. 
 
Silver Enhancement 
Cells were rinsed with deionized water (2 X 5 min) following 0.02 M sodium citrate 
buffer, pH 7.0 (3x 5 min). Then, the grid was floated with specimen on freshly mixed 
developer for 1-8 min, or as directed in the instructions for the silver reagent. More or less 
time can be used to control particle size. With HQ Silver, a development time of 6 min gives 
15-40 nm round particles. The cells were rinse again with deionized water (3x 1 min) and 
mounted. Sections were viewed in a JEOL 1010 or a JEOL 1200 electron microscope (JEOL; 
Tokyo, Japan), and images were recorded on Kodak 4489 sheet films (Kodak; Rochester, 
NY). 
 
2.2.3.10 Immunofluorescence Confocal Microscopy of  2'-Fluo-AHC-c-di-AMP 
Indirect Immunofluorescence 
BMDCs analysed by confocal microscopy were putted on collagen-coated coverslips 
(BD BioCoat, BD Bioscience, USA) in 24 well plates (Nunc, Denmark). DCs were stimulated 
with 1.5 µM 2'-Fluo-AHC-c-di-AMP (Biolog) for 2 h. After incubation, cells were carefully 
washed with pre-warmed PBS and fixed by adding 3% PFA for 10 min at RT. Fixed cells on 
coverslips were quenched for 15 min in 50 mM glycine in PBS. Subsequently, cells were 
permeabilized with 0.05% saponin in PBS containing 1% BSA, and then they were incubated 
1 h with the primary and 30 min with the secondary Abs. Finally, the nucleus staining was 
performed using 1 μg/ml DNA stain of Hoechst 33258. After staining, the coverslips were 
mounted on slides using aqueous mounting medium (Dako Cytomation, Denmark) and 
analysed by confocal microscopy (Leica SP5). 
 
2.2.3.11 Evaluation of type I IFN induction in reporter mice  
   To study the effect of c-di-AMP on the induction of IFN-β genes, global reporter 
albino C57BL/6 IFN-βΔβ-luc mice bred at HZI were used. Conditional reporter mice IFN-βfloxβ-luc 
were generated using C57BL/6 ES-cells (Bruce4). To replace the IFN-β CDS by luciferase in 
germ line (IFN-βΔβ-luc), IFN-βfloxβ-luc mice were crossed with K14cre mice [123]. To obtained 
conditional reporter mice expressing the luciferase gene under the control of on B cells, T 
cells, DCs and macrophages, IFN-βfloxβ-luc were crossed to CD19cre [124], CD4cre [125], 
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CD11ccre [126] and LysMcre [127] mice, respectively. The conditional reporter mice and 
IFNAR-/- mice received c-di-AMP by i.n. route at a concentration of 5 μg per mouse. IFN-β 
gene induction was analysed by measuring luciferase by in vivo imaging. To this end, mice 
were injected intravenously with 150 mg/kg of D-luciferin firefly (Synchem) dissolved in PBS 
at time points 0, 3, 6, 12 and 24 h after administration of c-di-AMP. Afterwards, mice were 
anesthetized with Isofluran® Curamed and monitored using the IVIS 200 imaging system 
(CaliperLS). Photon flux was quantified with the Live Imaging 3.2 Software (CaliperLS). 
 
2.2.3.12 Analysis of Mitogen-Activated Protein Kinases (MAPK) of J774 cells  
The Human Phosphor-MAPK Array Kit (The Proteome ProfilerTM Array from R&D, 
#ARY002) is a rapid, sensitive test, which can detect the relative levels of phosphorylation of 
nine MAPKs and other nine serine/threonine kinase. Several of the human antibodies of this 
kit are cross-reactive with mouse. Therefore, this kit was used to assess the protein kinase 
activation after c-di-AMP treatment of J774A.1 cells, according to the recommendations of 
the manufactures (see below).  
 
Cell lysates  
Cells were rinsed with PBS, making sure that any remaining PBS was removed 
before addition of the lysis buffer. Cells were then suspended at a concentration of 1 x 107 
cells/ml in Lysis Buffer 6, by pipetting up and down and they the resulting lysates were 
subsequent gently rocked at 2-8° C for 30 min. Then, the samples were centrifuged in a 
microcentrifuge at 14,000 x g for 5 min, and the supernatant fluids were transferred into a 
clean test tube. Protein concentrations were determined using the Pierce® BCA Protein 
assay kit. For incubation with the Human Phospho-MAPK Array, a quantity of lysate similar 
to that used for immunoprecipitation or Western blot (100 - 300 g) was used in a maximum 
lysate volume of 250 µl/array. Lysates were aliquoted and immediately stored at ≤ -70°C.  
 
Assay procedure  
Into each well of the 4-Well Multi-dish 1.5 mL of the Array Buffer 1 were pipetted. With 
a flat-tip tweezers, each array was removed from the protective sheets and one array into 
each well of the 4-Well Multi-dish was placed and incubated for 1 h on a rocking platform 
shaker. In a separate tube, the desired quantity of lysate to 1.25 mL of Array Buffer 1 was 
added. A final volume of 1.5 mL with Lysis Buffer 6 as necessary was adjusted. The 
maximum allowable lysate volume is 250 µl/array. The Array Buffer 1 from the 4-Well Multi-
dish was removed and the diluted lysates was added and incubated overnight at 2-8°C on a 
rocking platform shaker, covered with the lid. Each array was removed carefully and place 
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into individual plastic containers with 20 mL of 1x Wash Buffer. The 4-Well Multi-dish was 
rinsed with deionized or distilled water and dry thoroughly. Each array was washed with 1x 
Wash Buffer by soaking for 10 min on a rocking platform shaker. This was repeated two 
times for a total of three washes. For each array, 15 µL of Detection Antibody Cocktail 
Concentrate were diluted to 1.5 mL with 1x Array Buffer 2/3 and 1.5 mL/well of diluted 
Detection Antibody Cocktail were pipetted into the 4-Well Multi-dish. Then the array was 
returned to the 4-Well Multi-dish containing the diluted Antibody Cocktail Concentrate 
covered with the lid, and incubated for 2 h at RT on a rocking platform shaker. The washing 
described above was repeated and the Streptavidin-HRP was diluted 1:2,000 in 1x Array 
Buffer 2/3 and 1.5 mL were pipetted into each well of the 4-Well Multi-dish. After an 
incubation time of 30 min at RT on a rocking platform shaker each array was washed again, 
as described above. Carefully, each array from the wash container was removed and the 
excess Wash Buffer was drain from the array. Each array was exposed to chemiluminescent 
reagents by the use of luminol as a chemiluminescent agent, covered with plastic wrap and 
exposed to X-ray film for 5-10 min. The developed x-ray film is then quantified by scanning 
the film on transmission-mode scanner and the array analysed by Multi-Analyst (Bio-Rad 
Laboratories, Inc.).      
 
 
2.2.4 Characterization of the effector functions of c-di-AMP on human cells  
2.2.4.1 Generation of human monocytes-derived DCs and MΦs 
DCs were prepared from purified peripheral blood monocytes from healthy donors by 
density gradient centrifugation using Ficoll-Paque (GE Healthcare) and the CD14+ cells were 
isolated by depletion with magnetic beads (Monocyte isolation kit II, Miltenyi Biotec, 
Germany). For DC differentiation the CD14-enriched monocytes were cultured (1 x 106 
cells/ml) in complete culture medium RPMI 1640 with the addition of 25 ng/ml human rGM-
CSF and 25 ng/ml human recombinant IL-4 (Invitrogen, CA) in a humidified atmosphere 
containing 5% CO2 at 37°C. The medium was changed after 3 days, and on day 6 cells were 
used for stimulation with or without cyclic di-AMP for 24 h at 37°C. For MΦ differentiation the 
CD14-enriched monocytes were cultured (1 x 106 cells/ml) in complete culture medium RPMI 
1640 with the addition of 50 ng/ml human M-CSF (Invitrogen, CA) in a humidified 
atmosphere containing 5% CO2 at 37°C. On day 4, 1 ml of the medium was replaced with 1 
ml of fresh medium containing 50 ng of human M-CSF. On day 7, non-adherent cells were 
washed out and adherent cells were used as macrophages. 
 
 
   
  MATERIALS AND METHODS 
 
51 
 
 
2.2.4.2 Human allogeneic proliferation assay 
Immature DCs and c-di-AMP-treated DCs were washed three times, diluted in fresh 
complete medium, and used as allogenic stimulators. Cells were seeded in 96-well round-
bottom culture plates with 10,000 DCs/well, and were mixed along with freshly purified CD4+ 
or CD8+ T cells (100,000/well). After 3 days of incubation, cells were pulsed with 1 µCi of 
[3H] thymidine/well for 18 h and were harvested on filter paper. Proliferative responses were 
measured as [3H] thymidine incorporation by an automatic beta counter. Tests were 
performed in triplicates, and results were expressed as the mean cpm. 
 
2.2.4.3 Flow cytometry analysis of human cells  
Surface expression was determined using the co-stimulatory molecules CD80 and 
CD86, the maturation marker CD83, and HLA-DR (BD Pharmingen) (see Table 10). Human 
DCs were incubated in 1% human AB serum/PBS and incubated with rat anti-CD16/CD32 
(BD Pharmingen) to block nonspecific binding. Live cells were gated using forward (FSC) 
versus side scatter (SSC) dot plots. Samples were measured with the FACS machines LSRII 
(BD Bioscience, USA). Data obtained were analysed using FACS DiVA software (BD 
Bioscience, USA) or the software FlowJo Mac v8.84 (Tree Star, Inc., USA). 
 
 
2.2.5 Statistical analysis  
Statistical analyses were performed using the GraphPad software Version 5.03 and 
are displayed in the results part inside the figure legends. For multiple group comparisons, 
one-way ANOVA or two-way ANOVA were applied. For comparisons of independent groups, 
the Student‟s t test or the Mann-Whitney test were performed. For comparisons of matched 
groups, paired Student‟s t test or Wilcoxon matched test were performed. In figures, n.s. 
indicates not significant; *** indicates p < 0.001; ** indicates p < 0.01; and * indicates p < 
0.05. 
   
  RESULTS 
 
52 
 
3. CHAPTER: RESULTS  
 
3.1 Adjuvanticity of cyclic di-nucleotides 
 
To perform a comparative analysis of the adjuvant properties of cyclic di-nucleotides, 
mice were vaccinated by mucosal route with the model antigens ß-Gal or OVA co-
administered with either c-di-AMP, c-di-GMP or c-di-IMP. First, characterization studies were 
carried out to assess the degree of purity and biological activity of the candidate adjuvants. 
 
3.1.1  Analysis of the purity of the cyclic di-nucleotides with the HEK-BlueTM LPS 
 Detection assay 
The HEK-BlueTM LPS Detection assay is based on the ability of TLR4 to recognize 
structurally different LPS from Gram-negative bacteria and in particular the lipid A portion, 
their toxic moiety. Thus, to rule out LPS contamination, which can in term affect both in vitro 
and in vivo readouts, the synthesized compounds c-di-AMP, c-di-GMP and c-di-IMP were 
tested using the HEK-BLUETM LPS detection kit, according to the manufacturer‟s instructions. 
When tested at concentrations up to 10 μg/ml, the different batches of cyclic di-nucleotides 
showed no LPS contamination (detection limit, 0.3 ng/ml), as seen in Figure 5. 
 
 
Figure 5: HEK-Blue-based LPS detection.  
LPS contamination of the batches from the synthesized compounds was tested by the HEK-BLUE LPS detection 
kit. The cyclic di-nucleotides showed no LPS contamination. 
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3.1.2 Analysis of biological activity of the cyclic di-nucleotides - NO-release assay 
For the analysis of the potential of cyclic di-nucleotides to induce nitric oxide (NO)-
release in macrophages, the cells present in peritoneal exudates from C3H/HeJ LPS non-
responder mice were simultaneously stimulated with IFN-y (62.5 U/ml) and serial dilutions of 
c-di-AMP, c-di-GMP and c-di-IMP. After a 45 h incubation period, the nitrate is reduced by 
the nitrite reductase, and the presence of NO is determined as the sum of nitrite and nitrate 
using the Griss reagent.  
The obtained results showed that only c-di-IMP and c-di-AMP induce efficient NO 
release in pre-activated macrophages (Figure 6). The minimal concentration required for 
macrophage stimulation by cyclic di-AMP was 60 ng/ml, whereas much higher 
concentrations of c-di-IMP were needed to induce weak release of NO. No NO release was 
observed under these experimental conditions when cells were treated with c-di-GMP. 
 
 
Figure 6: Macrophage activation by c-di-AMP, c-di-GMP and c-di-IMP.  
Cells obtained from peritoneal exudates from C3H/HeJ LPS non-responder mice were simultaneously stimulated 
with IFN-y (to activate the macrophages) and serial dilutions of the candidate adjuvants c-di-GMP, c-di-AMP or c-
di-IMP. Results were expressed as the arithmetic means of the optical densities (OD 550 nm) of triplicates. 
 
3.1.3 The c-di-nucleotides induce strong humoral immune responses after i.n. 
immunization 
To analyse the capacity of the cyclic di-nucleotides to act as a mucosal adjuvant in 
vivo, BALB/c mice were immunized with the model antigen ß-Gal (15 µg/dose) alone or co-
administered with c-di-AMP, c-di-GMP or c-di-IMP by the i.n. route. The B subunit of the 
cholera toxin (CTB), which is a well-known adjuvant, was used as a golden standard. The 
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humoral immune responses stimulated after vaccination were characterized by determining 
the systemic production of antigen-specific IgG in sera and local IgA, IgM and the secretory 
component (SC; IgR) in nasal, vaginal and lung lavages by ELISA. As shown in Figure 7, a 
significant increment in ß-Gal-specific IgG-titres was observed in sera from animals receiving 
the c-di-nucleotides, in comparison to animals vaccinated with the antigen alone or co-
administered with CTB.   
 
 
Figure 7: Systemic humoral immune responses stimulated in BALB/c mice vaccinated using c-di-AMP, c-
di-GMP and c-di-IMP as mucosal adjuvants.  
Kinetic analysis of anti-ß-Gal IgG responses in sera from BALB/c mice (n=5) immunized on day 0, 14 and 28 with 
PBS (control),  ß-Gal alone (15 µg/dose) or  ß-Gal co-administered with 5 µg/dose of c-di-AMP, c-di-GMP, c-di-
IMP or CTB by the intranasal route. Differences were statistically significant at p<0.001 with respect to BALB/c 
mice receiving antigen alone (***). One representative out of four independent experiments is shown. The results 
are expressed as end point titres. The S.E.M. is indicated by vertical lines. 
 
 
Then, the stimulation of mucosal immune responses by the c-di-nucleotides was 
evaluated by measuring antigen-specific IgA, IgM and SC titres in nasal, lung and vaginal 
lavages from vaccinated animals (Figure 8). The i.n. immunization with ß-Gal co-
administered with c-di-nucleotides induced strong antigen-specific IgA responses in all the 
analysed mucosal territories. In contrast, antigen-specific IgA was not detected in lavage 
samples from mice receiving ß-Gal alone (p<0.001). To rule out the potential contribution of 
transudating antigen-specific IgA and IgM, the results were further confirmed by an ELISA 
which specifically detects the polymeric immunoglobulin receptor (i.e. SC). There was a 
significant increment of antigen-specific Ig with SC in lavage samples from mice vaccinated 
with the formulations containing c-di-AMP, c-di-GMP or c-di-IMP (Figure 8 A-C). 
0 14 28 42
0
2.0 106
4.0 106
6.0 106
8.0 106
Control 
ß-Gal
ß-Gal + c-di-GMP
ß-Gal + c-di-AMP
ß-Gal + c-di-IMP ***
***
***
ß-Gal + CTB
time (d)
A
n
ti
g
e
n
-s
p
e
c
if
ic
 I
g
G
 t
it
re
 i
n
 s
e
ra
   
  RESULTS 
 
55 
 
 
Figure 8: Humoral immune responses stimulated in BALB/c mice vaccinated using c-di-nucleotides as 
mucosal adjuvant.  
Analysis of the antigen-specific IgA, IgM and secretory Ig (sIg) expression A) in nasal (NL), B) lung (LL) and C) 
vaginal lavages (VL) of immunized mice. Fourteen days after the last immunization lavage samples of vaccinated 
mice were analysed by ELISA. Results are expressed as end point titres. The S.E.M. is indicated by vertical lines. 
Differences were statistically significant at p<0.001 (***), p<0.01 (**) or p<0.05 (*) with respect to BALB/c mice 
receiving antigen alone. One representative out of three independent experiments is shown. 
 
 
3.1.4 Induction of cellular immune responses after i.n. immunization 
Lymphoproliferative assays were carried out to evaluate the capacity of c-di-
nucleotides to promote cellular immune responses. To this end, splenocytes isolated 42 days 
after the first immunization were re-stimulated in vitro with the ß-Gal protein. The strongest 
proliferative responses were observed in cells from mice receiving ß-Gal with c-di-AMP 
followed by those from mice vaccinated using c-di-IMP, CTB or c-di-GMP as adjuvants 
(Figure 9). In contrast, no responses were observed when splenocytes from mice immunized 
with the ß-Gal protein alone were tested.  
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Figure 9: Evaluation of the cellular responses stimulated in mice vaccinated using c-di-nucleotides as 
mucosal adjuvant.  
Spleen cells from vaccinated animals were re-stimulated with different concentrations of β-Gal for 96 h. Cellular 
proliferation was then assessed by determination of the [
3
H]-thymidine incorporated into the DNA of replicating 
cells. Results are averages of quadruplicates and they are expressed as stimulation indexes (SI). The S.E.M. is 
indicated by vertical lines. Differences were statistically significant at p<0.001 (***) or p<0.05 (*) with respect to 
values from cells of BALB/c mice receiving antigen alone. One representative out of three independent 
experiments is shown. 
 
 
3.1.5 Stimulation of antigen-specific CD8+ T cells after vaccination with c-di-
nucleotides as adjuvants 
Depending on the pathogen (e.g. viruses), the stimulation of a vigorous cytotoxic T 
cell response after vaccination could be essential in order to induce efficient protective 
immunity. Thus, the potential of c-di-nucleotides to elicit cytolytic activity of T cells was 
analysed. To evaluate whether c-di-AMP, c-di-GMP or c-di-IMP are able to induce antigen-
specific cytolytic T cells, C57BL/6 mice were immunized three times with 30 µg OVA alone or 
co-administrated with 5 µg of the c-di-nucleotides by the i.n. route. Four weeks after the last 
immunization, OVA-peptide loaded CFSE+ spleen cells obtained from naïve animals were 
intravenously injected to the vaccinated mice and the capacity of CTL stimulated by 
vaccination to lyse them in vivo was further evaluated by flow cytometry. The obtained 
results showed that OVA-specific cytolytic T cells were able to lyse antigen-specific target 
cells in animals immunized with OVA co-administered with c-di-AMP, c-di-GMP or c-di-IMP. 
Approximately 64%, 28% and 65% of the peptide loaded cells were lysed in vivo, 
respectively, whereas in mice vaccinated with the antigen alone only a weak (11%) OVA-
specific lysis was observed (Figure 10).  
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Figure 10: OVA-specific in vivo CTL activity in vaccinated mice.  
Assessment of the effect of co-administration of c-di-nucleotides on CTL responses as measured by the VITAL 
assay (in vivo CTL). Four weeks after the last boost, the lysis of CFSE
+
, OVA-peptide loaded splenocytes was 
monitored relative to unloaded splenocytes in immunized mice (n=4). The percentage of specific lysis for each 
group of four animals is shown. The S.E.M. is indicated by vertical lines. Differences were statistically significant 
at p<0.001 (***) or p<0.01 (**) with respect to BALB/c mice receiving antigen alone. One representative out of 
three independent experiments is shown. 
 
Furthermore, the adjuvanticity effect of the cyclic di-nucleotides was proven also with the 
antigen OVA. Therefore, the C57BL/6 mice were immunized as described above and the 
systemic production of OVA-specific IgG in sera and local IgA in nasal, vaginal and lung 
lavages were determined by ELISA (Figure 11A-B). 
As shown in Figure 11AFigure 7, a significant increment in OVA -specific IgG-titres was 
observed in sera from animals receiving the c-di-nucleotides, in comparison to animals 
vaccinated with the antigen alone.  
Moreover, the stimulation of mucosal immune responses by the c-di-nucleotides was 
evaluated by measuring antigen-specific IgA titres in nasal, lung and vaginal lavages from 
vaccinated animals (Figure 11B). The i.n. immunization with OVA co-administered with c-di-
nucleotides induced strong antigen-specific IgA responses mainly in the nasal cavity. 
However, an increment of OVA-specific IgA titre in the lung lavage (5-fold) and vaginal 
lavage (3-fold) samples of animals immunized with OVA+ c-di-AMP could be also observed, 
in contrast to mice vaccinated with the antigen alone.  
Then, proliferative responses were observed in splenocytes derived from OVA 
vaccinated C57BL/6 mice. Therefore, splenocytes isolated 42 days after the first 
immunization were re-stimulated in vitro with the OVA protein and the proliferation capacity 
was measured as [3H]-thymidine incorporation. As shown in Figure 11C the strongest 
proliferative responses were observed in cells from mice receiving OVA with c-di-AMP 
followed by those from mice vaccinated using c-di-GMP as adjuvants. In contrast, only a 
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weak response was observed in splenocytes from mice immunized with c-di-IMP as adjuvant 
and no response when OVA alone were tested. 
 
 
Figure 11: Evaluation of OVA-specific immune responses stimulated in C57BL/6 mice vaccinated using c-
di-AMP as mucosal adjuvant. 
A) Analysis of OVA-specific serum IgG titres in mice (n=5) immunized by the intranasal route three times (day 0, 
14 and 28) with PBS, OVA alone (30 µg per dose) or OVA co-administered with c-di-AMP, c-di-GMP or c-di-IMP 
(5 µg) by ELISA. Results are expressed as end point titres. Differences were statistically significant at p<0.001 
(***) or p<0.01 (**) with respect to values in C57BL/6 mice receiving antigen alone. The S.E.M. is indicated by 
vertical lines. One representative experiment out of three is shown. B) Analysis of antigen-specific IgA in nasal, 
lung and vaginal lavages. Results are expressed as OVA-specific IgA titres per µg of total IgA. The S.E.M. is 
indicated by vertical lines. Differences were statistically significant at p<0.05 (*) with respect to values in C57BL/6 
mice receiving antigen alone. C) Proliferative responses stimulated in mice immunized using c-di-AMP, c-di-GMP 
or c-di-IMP as adjuvants. Spleen cells from vaccinated animals were re-stimulated with different concentrations of 
OVA for 96 h. Cellular proliferation was then assessed by determination of the [
3
H]-thymidine incorporated into 
the DNA of replicating cells. Results are averages of quadruplicates and they are expressed as counts per minute 
(cpm). Differences were statistically significant at p<0.001 (***) with respect to values from cells of C57BL/6 mice 
receiving antigen alone. One representative experiment out of three is shown. 
 
 
3.1.6 Induction of a balanced Th1/Th2/Th17 T helper immune response after 
vaccination with c-di-nucleotides as adjuvants  
To assess the effect on T helper responses resulting from using c-di-nucleotides as 
mucosal adjuvant, the subclasses of ß-Gal-specific serum IgG were first analysed (Figure 
12). The production of IgG1 indicates a Th2 immune response, whereas IgG2a is stimulated 
during a Th1 dominated response. The obtained results revealed a balanced IgG1/IgG2a 
response in animals receiving ß-Gal co-administered with c-di-nucleotides, whereas in 
animals receiving only antigen a weak production of antigen-specific IgG subclasses was 
shown (Figure 12). In contrast, control mice receiving CTB developed a Th2 biased 
response, characterized by enhanced expression of the IgG1-subclass. These results 
suggested the stimulation of a balanced Th1/Th2 immune response in mice vaccinated with 
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c-di-nucleotides. The highest titres were observed in animals vaccinated using c-di-AMP as 
adjuvant, followed by those immunized with c-di-GMP and c-di-IMP.  
 
 
Figure 12: Analysis of antigen-specific IgG isotypes stimulated in vaccinated animals. 
Analysis of ß-Gal-specific IgG subclasses in sera of immunized mice (n=5) by ELISA. Differences were 
statistically significant at p<0.001 with respect to BALB/c mice receiving antigen alone (***). One representative 
out of four independent experiments is shown. Results are expressed as end point titres. The S.E.M. is indicated 
by vertical lines. 
 
 
Then, we analyzed the levels of cytokines secreted by lymphocytes from vaccinated 
animals. To this end, the presence of ß-Gal-specific IFN-y, IL-2, IL-4 and IL-17 secreting 
cells was assessed by ELISPOT (Figure 13). Splenocytes from mice immunized with antigen 
co-administered with c-di-nucleotides predominantly secreted IL-17 in response to ß-Gal 
antigen alone, followed by IL-2, IL-4 and IFN-y. The higher number of IFN-y producing cells 
were observed in cells from animals receiving c-di-GMP as adjuvant. Similar qualitative 
results were obtained when cells from control mice receiving CTB as adjuvant were tested, 
but with a much lower absolute number of cytokine producing cells (Figure 13).  
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Figure 13: Analysis of Th-specific cytokines in immunized mice.  
Spleen cells recovered from vaccinated mice were incubated for 24 or 48 h in the  presence of a peptide 
encompassing the immunodominant Ld-restricted epitope of β-Gal (TPHPARIGL), which is specific for MHC class 
I presentation (for IFN-γ), or the β-Gal protein (for IL-2, IL-4 and IL-17). Then, the numbers of cytokine producing 
cells was determined by ELISPOT. Results are presented as spot forming units per 10
6
 cells, which were 
subtracted from the values obtained from non-stimulated cells. One representative experiment out of three is 
shown. Differences were statistically significant at p<0.001 with respect to values in BALB/c mice receiving 
antigen alone (***). S.E.M. is indicated by vertical lines. 
 
 
To further confirm these data, the cytokine secretion pattern of splenocytes from 
vaccinated animals was determined after in vitro re-stimulation. To this end, spleen cells 
were incubated in vitro with different concentrations of ß-Gal for 4 days and the concentration 
of Th1 (IFN-y, TNFα, IL-2), Th2 (IL-1, IL-4, IL-6, IL-10) and Th17 (IL-17) specific cytokines 
were analysed (Figure 14 and Figure 15).  
In animals vaccinated with ß-Gal co-administered with c-di-nucleotides by i.n. route a 
strong increase of IFN-y was measured. When cells from animals receiving c-di-AMP as 
adjuvant were tested, approximately 3-fold higher production of cytokines was observed, as 
compared to those from mice vaccinated with c-di-GMP or c-di-IMP. Only cells from mice in 
which ß-Gal was co-administered with c-di-IMP showed strong IL-2 production. Concerning 
Th2 cytokines, an increased secretion of IL-6 and IL-10 was observed in mice immunized 
with the c-di-nucleotides (Figure 14).  
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Figure 14: ß-Gal-specific cytokine secreting cells in mice immunized with ß-Gal co-administered with c-di-
nucleotides.  
Cells were re-stimulated in quadruplicates with different concentrations of ß-Gal for 96 h. The cytokines secreted 
by spleen cells were then evaluated by a Th1/Th2 Flowcytomix array. Results are expressed in pg/ml. One 
representative experiment out of tree is shown. Differences were statistically significant at p < 0.01 (***), p < 0.01 
(**) or p < 0.05 (*) with respect to values of cells from BALB/c mice receiving the antigen alone. S.E.M. is 
indicated by vertical lines. 
 
 
The Th17 cytokine IL-17 was strongly up-regulated in the groups of mice immunized 
with all three c-di-nucleotides. However, mice receiving c-di-AMP as adjuvant showed 
approximately 2–fold higher levels of IL-17 secretion than those immunized with either c-di-
GMP or c-di-IMP (Figure 15).  
 
Figure 15: ß-Gal-specific IL-17 secretion by cells from mice immunized with ß-Gal co-administered with c-
di-nucleotides. 
Spleen cells were re-stimulated in quadruplicates with different concentrations of ß-Gal for 96 h. The cytokines 
secreted by cells were then evaluated using a Th1/Th2 Flowcytomix array. Results are expressed in pg/ml. One 
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representative experiment out of three is shown. Differences were statistically significant at p < 0.001 (***) with 
respect to values from cells of BALB/c mice receiving the antigen alone. S.E.M. is indicated by vertical lines. 
 
 
The performed studies demonstrated that immunization with antigen co-administered 
with c-di-AMP, c-di-GMP or c-di-IMP by the mucosal route resulted in enhanced humoral and 
cellular immune responses and revealed a balanced Th1/Th2/Th17 immune responses. 
However, there are some differences in the potency of these small molecules, suggesting 
that c-di-AMP exerts the most potent adjuvant activity. This makes this compound the most 
promising for further development. Therefore, the following studies were focussed on the 
elucidation of the effector functions and underlying mechanisms of action of c-di-AMP.  
 
 
3.2 In vitro studies to assess the effector functions of c-di-AMP on 
APCs 
 
APCs are cells that convert protein antigens into peptides and present them through 
MHC complexes on their surface. While all nucleated cells express MHC-class I that allow to 
present peptides derived antigens, only specialized cells, the APCs (e.g. DCs, MΦs and B 
cells), have the appropriate machinery for the processing and presentation of extracellular 
antigens through the MHC-class II molecules. Moreover, APCs are capable of priming and 
sustaining the expansion of naïve T cells. Further, mature DCs can elicit the activation of 
other innate immune cells, such as NK cells, by secretion of cytokines (e.g. type I IFNs).  
 
3.2.1 Activation and maturation of APCs after stimulation with c-di-AMP 
DCs play a central role in bridging innate and adaptive immune responses. Activation 
can occur via binding of PRR by PAMPs, also defined as danger signals, which are derived 
from viruses, bacteria, fungi and protozoa. PAMP-mediated stimulation of DCs triggers their 
differentiation into immunogenic APCs, which are able to prime and sustain the expansion of 
naïve T cells [128]. Therefore, the effector functions of c-di-AMP on DCs were investigated 
by evaluating its capacity to trigger differentiation and maturation of bone marrow-derived 
murine DCs.  
The obtained results demonstrated that c-di-AMP was able to promote an efficient 
activation and maturation of DCs in vitro, when used at a final concentration of 1 μg/ml. The 
analysis by FACS showed an enhanced expression of MHC class II, co-stimulatory (CD80, 
CD86), and activation (CD40) molecules (Figure 16). 
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Figure 16: Flow cytometric analysis of DCs after stimulation with c-di-AMP. 
A) BM-derived murine DCs were co-incubated with c-di-AMP (1 μg/ml) (blue line) and LPS (black line) for 24 h 
and analysed by flow cytometry. Cells incubated in medium alone (grey shaded area), were used as controls. The 
expression of the surface markers CD40, CD80, CD86, and MHC class II on CD11c+-gated cells is shown. B) 
The relative expression of each activation marker was expressed as a fold increase: the MDFI (of CD11c
+
 cells) 
resulting from staining for CD40, CD80, CD86, or MHC class II of stimulated DCs was divided by the MDFI due to 
staining for the same markers of non-stimulated CD11c
+
 DCs (negative controls). Data represents the mean with 
the SEM of 4 experiments. Differences were statistically significant at p<0.001 (***) or p<0.05 (*) with respect to 
non-stimulated DCs.  
 
 
In order to analyse the capacity of c-di-AMP to stimulate the activation and maturation 
of murine MΦs, immature bone-marrow derived macrophages (BMMΦ) were stimulated in 
vitro with c-di-AMP for 24 h. As shown in Figure 17, pre-treatment with 1 μg/ml of c-di-AMP 
for 24 h resulted in an increased expression of CD40, CD86 and MHC-II, in comparison to 
negative controls and LPS stimulated positive control cells (the analysis was performed 
gating on CD11b+ vital cells).  
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Figure 17: Flow cytometric analysis of BM-derived MΦ after stimulation with c-di-AMP.  
A) MΦs were incubated in medium supplemented with c-di-AMP (1 μg/ml) (blue line) or LPS (black line) for 24 h 
and then analysed by flow cytometry, control cells were culture in medium alone (grey shaded area). The 
expression of the surface markers CD40, CD80, CD86 and MHC class II on CD11b+-gated cells is shown. B) The 
relative expression of each activation marker was expressed as a fold increase: the MDFI (of CD11b
+
 cells) after 
staining for CD40, CD80, CD86 or MHC class II (for the stimulated DCs) was divided by the MDFI for the same 
activation markers of non-stimulated CD11b
+
 DCs (negative controls). Data represents the mean of 3 
experiments. The SEM is indicated by vertical lines. Differences were statistically significant at p<0.001 (***) with 
respect to non-stimulated MΦs.  
 
 
To further investigate the stimulatory capacities of c-di-AMP on APCs, splenic cells 
were first sorted for CD19+CD21+CD23+ follicular (FO) B cells, which constitute the majority 
of B cells found in secondary lymphoid tissue. Then, the sorted B cells were stimulated in 
vitro with c-di-AMP for 5 days. Their proliferation capacity was measured as [3H]-thymidine 
incorporation (Figure 18A), and the expression of activation markers (Figure 18B) were 
determined. The treatment of sorted B cells with 1 μg/ml of c-di-AMP resulted in a marginal 
proliferation. Furthermore, the analysis by FACS showed no increased expression of CD40, 
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CD80, CD86 and MHC-II markers, in comparison to MALP-2 or LPS stimulated positive 
control cells.  
                                          
 
 
Figure 18: Flow cytometric analysis of B cells after stimulation with c-di-AMP.  
A) B cells were incubated in medium alone (grey shaded area) or supplemented with either c-di-AMP (1 μg/ml; 
blue line), LPS (1 µg/ml; black line) or MALP-2 (1 µg/ml; gray line) for 24 h and then analysed by flow cytometry. 
The expression of the surface markers CD40, CD80, CD86, and MHC class II on CD19
+
-gated cells is shown. B) 
B cells were incubated in medium alone or supplemented with c-di-AMP, LPS or MALP-2 for 5 days. Then, B cell 
proliferation was assessed by determination of the [
3
H]-thymidine incorporated into the DNA of replicating cells. 
Results are averages of quadruplicates and they are expressed as cpm. Differences were statistically significant 
at p<0.001 (***) or p<0.01 (**) with respect to non-stimulated B cells. S.E.M. is indicated by vertical lines.  
 
 
 
3.2.2 Examination of the T cell proliferation induced by c-di-AMP stimulated DCs 
Next, the capacity of DCs loaded with OVA in the presence of c-di-AMP to stimulate 
proliferation of antigen-specific CD8+ and CD4+ T cells was evaluated. DCs stimulated with 1 
μg/ml c-di-AMP were able to induce a strong proliferation of OVA-specific CD8+ from OT-I 
mice, as shown by the loss of CFSE+ stained cells (Figure 19). Furthermore, c-di-AMP pre-
activated DCs were also able to stimulate the proliferation of CD4+ T cells derived from 
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DO.11.10 mice. DCs loaded with OVA in the presence of 1 μg/ml LPS were also able to 
stimulate the proliferation of CD8+ and CD4+ T cells. Nevertheless, weaker T cell proliferation 
was observed when DCs were loaded with the antigen alone.  
 
 
 
Figure 19: T cell proliferation induced by c-di-AMP stimulated DCs 
Bone marrow-derived DCs were incubated for 24 h with LPS-free OVA (10 μg/ml) in the presence of c-di-AMP (1 
μg/ml). Non-stimulated pulsed DCs were used as controls. Then, the loaded DCs were cultured with either CFSE 
labelled naïve CD8
+
 or CD4
+
 T cells from OT-I or DO.11.10 mice for 4 days and further analysed by flow 
cytometry. The results are expressed as histograms and the percentage of the proliferated OT-I and DO.11.10 T 
cells (black line) with respect to non-stimulated DCs is shown. One experiment out of five independent 
experiments is shown. 
 
 
3.2.3 Capability of c-di-AMP to induce a direct CD8+ and CD4+ T cell proliferation 
Adjuvants can act as non-specific mediators of immune cell function by stimulating or 
modulating immune cells, but should not have any specific antigenic effect per se.  
Therefore, we assess the ability of c-di-AMP to stimulate the proliferation of CD4+ and CD8+ 
T cells. To this end, sorted T cells derived from spleens of BALB/c mice were stimulated with 
or without c-di-AMP (1 μg/ml) or ConA (5 µg/ml), as positive control. The adjuvant was not 
able to induce a significant proliferation of specific CD4+ or CD8+, as shown in Figure 20. 
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Figure 20: Influence of c-di-AMP on CD4
+
 and CD8
+
 T cells.  
Spleen cells from BALB/c mice were sorted for naïve CD4
+ 
(CD62L
high
CD44
low
CD25
-
)
 
or CD8
+ 
(CD62L
hich
CD44
low
CD25
-
)
 
T cells, which were then left untreated or stimulated for 4 days with either c-di-AMP (1 
µg/ml) or ConA (5 µg/ml), as a positive control. Cellular proliferation was then assessed by determination of the 
[
3
H]-thymidine incorporated into the DNA of replicating cells. Results are averages of quadruplicates and they are 
expressed as cpm. The S.E.M. is indicated by vertical lines. Differences were statistically significant at p<0.001 
(***) or non-significant (n.s.) with respect to non-stimulated T cells. 
 
 
3.2.4 In depth analysis of effector functions of c-di-AMP on different DCs subsets 
The initial studies on the effector functions of c-di-AMP on different cell population 
suggested that DCs represent the main target for the observed immune modulatory activities. 
Thus, we next examined its effector functions on specific DC subsets. To this end, BMDCs 
were pre-incubated with Flt3L to promote their differentiation in a mixed DC population. After 
9 days of differentiation the cells were stimulated with c-di-AMP or LPS as positive control for 
24 h and stained for the specific subset markers CD11c+CD11b+  from cDCs, which consist of 
different subtypes including CD8- myeloid DCs (mDCs) and CD8+ lymphoid DCs (lDCs), and 
the CD11c+CD11b-B220+ pDCs (Figure 21). 
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Figure 21: Gating strategy used to identify DC subsets stimulated in the presence or absence of c-di-AMP 
or LPS.  
The percentage of each boxed cell population is indicated. Doublets were excluded by forward scatter area (FSC-
A) versus forward scatter height (FSC-H). Dead cells were excluded by their staining with a fluorescent reactive 
dye. 
 
 
The effect of c-di-AMP on DC subsets was then investigated in terms of differentiation 
and maturation of murine BMDC subsets. The c-di-AMP was able to promote an efficient 
activation and maturation of cDCs in vitro when used at a final concentration of 5 μg/ml. The 
analysis by flow cytometry showed a significant expression of the co-stimulatory markers 
CD80 and CD86 in lDCs, followed by mDCs. Only a weak expression of the CD86 molecule 
and no up-regulation of the CD80 molecule were observed in pDCs after c-di-AMP 
stimulation (Figure 23 A-C). LPS was also able to stimulate all DC subsets at a concentration 
of 1 μg/ml. 
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Figure 22: Flow cytometric analysis of DC subsets after stimulation with c-di-AMP in vitro.  
BMDCs from BALB/c mice were differentiated by Flt3L for 9 days. Cells were then stimulated with or without c-di-
AMP (1 µg/ml and 5 µg/ml) or LPS (1µg/ml) for 24h. DCs were then stained using a cell viability markers and Abs 
specific for the DC subsets. The plotted data represent histograms and the average of A) CD11c
+
CD11b
+
CD8
-
 
MHC-II
+
 mDCs, B) CD11c
+
CD11b
+
CD8
+
 MHC-II
+
 lDCs, and C) CD11c
+
CD11b
-
B220
+
MHC-II
+ 
pDCs expressing 
the co-stimulatory markers CD80 and CD86. One representative histogram of non-stimulated DCs (grey shaded 
area), c-di-AMP stimulated DCs (blue line), and/or LPS stimulated DCs (black line). Differences were statistically 
significant at p<0.001 (***), p<0.01 (**) or p<0.05 (*) with respect to non-stimulated DCs.  
 
 
3.2.5 Quantification of intracellular cytokine production by DC subsets after c-di-
AMP stimulation 
The capacity of mature DCs to prime naïve T lymphocytes and to promote their 
differentiation into different T cell subsets is not only attributed to the up-regulation of surface 
MHC, co-stimulatory and adhesion molecules, but also on the ability to secrete cytokines 
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such as IL-1, IL-6, IL-7, IL-12, IL-15, and IL-18. In fact, the secretion of IL-12 is critical for 
immune responses against many viruses and intracellular bacterial pathogens. The release 
of IL-12 by DCs increases NK cell- and T cell mediated cytotoxicity and stimulates IFN-y 
production and proliferation of NK cells and T cells. Therefore, the pattern of cytokine 
expression during DC subset stimulation with c-di-AMP or LPS was assessed by intracellular 
staining, followed by flow cytometric analysis. The DC subsets were defined as described 
above in the gating strategy (Figure 21).  
 
 
 
Figure 23: Detection of intracellular cytokine production by DC subsets stimulated with c-di-AMP. 
BMDCs from BALB/c mice were differentiated by Flt3L for 9 days. Cells were then stimulated with or without c-di-
AMP (1 µg/ml and 5 µg/ml) or LPS (1µg/ml) for 20 h. DCs were then stained using a cell viability markers and Abs 
specific for CD11c, CD11b, CD220 and CD8. After permeabilization, intracellular staining was performed using 
Abs specific for IL-12p40. The plotted data represent the percentage of CD11c
+
CD11b
+
CD8
+
 lDCs (green frame), 
CD11c
+
CD11b
+
CD8
-
 mDCs (orange frame), and CD11c
+
CD11b
-
B220
+ 
pDCs (red frame) producing IL-12p40. The 
numbers within the quadrants indicate the percentages of cells. 
 
 
The obtained results showed an increased secretion of IL-12p40 by all three DC 
subsets after stimulation with 5 μg/ml of c-di-AMP (Figure 23 and Figure 24). However, a 
strong secretion was observed in the cDC subsets (mDCs and lDCs) even with lower 
concentration of 1 μg/ml c-di-AMP. In contrast, marginal amount of IL-12p40 are secreted by 
pDCs after c-di-AMP stimulation. Stimulation with LPS resulted in a lower cytokine 
production as compared to c-di-AMP, moreover, the LPS stimulated lDCs showed an 
inhibition of IL-12p40 production (Figure 23 and Figure 24).   
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Figure 24: Detection of intracellular IL-12 in BMDC subsets stimulated with c-di-AMP. 
BMDCs from BALB/c mice were differentiated by Flt3L for 9 days. After DC stimulation with or without c-di-AMP 
(1 µg/ml and 5 µg/ml) or LPS (1µg/ml) for 20 h, cells were stained using a cell viability marker and Abs specific for 
CD11c, CD11b, B220 and CD8. After permeabilization, intracellular staining was performed using Abs specific for 
IL-12p40 The bars represent the median fluorescence intensity (MDFI) of CD11c
+
CD11b
+
CD8
+
 lDCs, 
CD11c
+
CD11b
+
CD8
-
 mDCs, and CD11c
+
CD11b
-
B220
+ 
pDCs producing IL-12p40. The S.E.M. is indicated by 
vertical lines Differences were statistically significant at p<0.001 (***) or p<0.05 (*) with respect to non-stimulated 
DCs. 
 
 
Next, the intracellular secretion of the IL-10 cytokine was investigated in cDCs. IL-10 
can inhibit the release of IL-12, thereby down regulating the Th1 response. The obtained 
results showed an increased secretion of IL-10 in cDC after stimulation with either 1 µg/ml or 
5 μg/ml of c-di-AMP (Figure 25). Treatment on control cells with LPS does not result in any 
significant increase of IL-10 production in comparison to untreated DCs. 
un
tr
ea
te
d
c-
di
-A
M
P 
1µ
g/
m
l
c-
di
-A
M
P 
5µ
g/
m
l
LP
S
 1
µg
/m
l
0
100
200
300
400
2,000
4,000
6,000
8,000
10,000
lymphoid DCs
***
***
in
tr
a
c
e
ll
u
la
r 
IL
1
2
p
4
0
 c
y
to
k
in
e
 d
e
te
c
ti
o
n
 i
n
 B
M
D
C
 s
u
b
s
e
ts
 (
M
D
F
I)
un
tr
ea
te
d
c-
di
-A
M
P 
1µ
g/
m
l
c-
di
-A
M
P 
5µ
g/
m
l
LP
S
 1
µg
/m
l
0
100
200
300
400
2,000
4,000
6,000
myeloid DCs
***
***
in
tr
a
c
e
ll
u
la
r 
IL
1
2
p
4
0
 c
y
to
k
in
e
 d
e
te
c
ti
o
n
 i
n
 B
M
D
C
 s
u
b
s
e
ts
 (
M
D
F
I)
un
tr
ea
te
d
c-
di
-A
M
P 
1µ
g/
m
l
c-
di
-A
M
P 
5µ
g/
m
l
LP
S
 1
µg
/m
l
0
20
40
60
80
100
120
plasmacytoid DCs
*
***
***
in
tr
a
c
e
ll
u
la
r 
IL
1
2
p
4
0
 c
y
to
k
in
e
 d
e
te
c
ti
o
n
 i
n
 B
M
D
C
 s
u
b
s
e
ts
 (
M
D
F
I)
   
  RESULTS 
 
72 
 
 
Figure 25: Detection of the intracellular IL-10 in BMDC subsets stimulated with c-di-AMP. 
BMDCs from BALB/c mice were differentiated by GM-CSF for 5 days. After DC stimulation with or without c-di-
AMP (1 µg/ml and 5 µg/ml) or LPS (1µg/ml) for 20 h, cells were stained using a cell viability marker and Abs 
specific for CD11 and CD11b. After permeabilization, intracellular staining was performed using Abs specific for 
IL-10. The bars represent the median fluorescence intensity (MDFI) of CD11c
+
CD11b
+
 cDCs producing the IL-10 
cytokine. The S.E.M. is indicated by vertical lines. Differences were statistically significant at p<0.01 (**) or non-
significant (n.s.) with respect to non-stimulated cells. 
 
 
3.3 Cyclic di-AMP exhibits strong stimulatory activity on human 
APCs in vitro 
 
Since c-di-AMP was showing a strong activation of murine DCs and MΦs it was 
essential to investigate the ability of c-di-AMP to induce the maturation and activation of 
human DCs. 
  
3.3.1 Human DC and MΦ activation and maturation after c-di-AMP treatment 
The potency of c-di-AMP to activate also human derived DCs and MΦs in vitro was 
investigated. First, human monocyte-derived DCs were prepared from PBMCs and cultured 
in the presence of GM-CSF for 5 days. Then, immature DCs were treated with different 
concentrations of c-di-AMP to define the amount of adjuvant needed for the up-regulation of 
the MHC class II (HLA-DR), co-stimulatory (CD80, CD86) and maturation (CD83) molecules 
(Figure 26 A-B). The obtained results showed an enhanced expression of MHC-II, CD80/86 
and CD83 starting at a concentration of 66 µg/ml of c-di-AMP. 
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Figure 26: Flow cytometric analysis of human DCs and MΦs after stimulation with c-di-AMP.  
PBMC-derived human DCs or MΦs were incubated for 24 h alone or in the presence of LPS, or c-di-AMP. A) 
Dose response of DCs to c-di-AMP stimulation for the CD80, CD86, and MHC-II molecules and maturation 
marker CD83 was investigated. B) PBMC-derived human DCs or MΦs were incubated for 24 h alone (grey 
shaded) or in the presence of either LPS (100 ng/ml, grey dotted line) or c-di-AMP (132 μg/ml; black line. Cells 
were then stained with fluorochrome conjugated Abs specific for CD80, CD83 (only for DCs), CD86, and MHC-II 
(HLA-DR), and further analysed by flow cytometry. Results correspond to an experiment performed with cells 
from a single donor and they are representative of three independent experiments tests. 
 
 
Afterwards, PBMC-derived human DCs and MΦs were treated with 132 µg/ml c-di-
AMP and 100 µg/ml LPS. As shown in Figure 26B a strong enhanced expression of the 
examined molecules could be observed in both, DCs and MΦs, after the treatment with c-di-
AMP.  
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3.3.2 Allogeneic T cell proliferation is induced by c-di-AMP stimulated DCs 
Allogeneic proliferation is a phenomenon, which was originally discovered in organ 
transplantation by mediating rejection. It is based on the ability of T cells to recognize non-
self MHC complexes leading to an Ag-independent proliferation. Roughly 1-10% of these T 
cells in an individual respond to stimulation with cells from another unrelated individual [32].  
To determine whether the c-di-AMP-treated human DCs have an enhanced ability to 
stimulate T cells, an allogeneic T cell proliferation assay was performed. Immature DCs, c-di-
AMP-treated DCs, and LPS-treated DCs were co-cultured with CFSE-labelled CD4+ or CD8+ 
T cells for 6 days, and then analysed by flow cytometry. 
The co-culture of c-di-AMP stimulated DCs resulted in a significant proliferation of naïve 
CD4+ T cells (DCs to T cell ratio 1:10) of about 36% (Figure 27). In contrast, un-stimulated 
DCs induced a proliferation of 25%, whereas LPS maturated DCs induced a proliferation of 
44%. However, at higher DC:T cell ratios similar proliferation was observed for DCs treated 
or not with c-di-AMP. In contrast to LPS-treated DCs, no increased proliferation of CD8+ T 
cells was observed when DCs were co-cultured with c-di-AMP.  
 
 
 
Figure 27: Allogeneic proliferation assay with human DCs and T cells.  
Human immature DCs were stimulated with c-di-AMP (132 µg/ml) or LPS (100 ng/ml) or left untreated (medium). 
After 24 h, DCs were co-cultured with purified CD4
+
 (A) and CD8
+
 (B) T cells at different ratios. On day 4 the cells 
were labelled with CFSE and analysed by FACS. Differences were statistically significant at p<0.001 (***), or 
p<0.01 (**) with respect to untreated DCs. S.E.M. is indicated by vertical lines. 
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3.4 In vivo analysis of the immune stimulatory capacities of  
c-di-AMP 
 
As already shown in the in vitro analysis, c-di-AMP was able to stimulate MΦs, DCs 
and DC subsets very efficiently. Thus, the ability of c-di-AMP to stimulate MΦs, DCs and 
their subsets in vivo was further investigated. To this end, BALB/c mice received c-di-AMP 
co-administrated with or without ß-Gal by i.n. route or MALP-2 as control. After 24 h, the 
expression of activation and maturation markers by DCs and MΦs from NALT and cLN was 
analysed ex vivo by flow cytometry.  
 
 
3.4.1 Activation and maturation of DCs and MΦs is induced in vivo by c-di-AMP  
The c-di-AMP was able to promote an efficient in vivo activation and maturation of 
DCs and MΦs in NALT when used at a concentration of 5 μg/dose (Figure 28). The analysis 
by FACS showed an enhanced expression of MHC class II, CD80 and CD86 in both DCs 
and MΦs.  
                
Figure 28: Flow cytometric analysis of DCs and MΦs in NALT after intranasal administration of c-di-AMP. 
Balb/c mice were intranasally treated with c-di-AMP (5 μg/dose; black line), MALP-2 (0.5 µg/dose; black dotted 
line) or PBS (grey shaded area). After 24 h, cells were isolated from the NALT and the expression of the surface 
markers CD80, CD86 and MHC class II was determined on CD11c
+
-gated cells (DCs) or CD11b
+
-gated cells 
(MΦ) by flow cytometry. One representative experiment out of three is shown.     
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Activation and maturation was also observed in DCs from cLN of c-di-AMP-treated 
mice. In contrast, in MΦs only the expression of CD80 and to less extends MHC class II were 
clearly up-regulated after treatment with c-di-AMP or MALP-2 (Figure 30).     
 
Figure 29: Flow cytometric analysis of DCs and MΦs in cLN after i.n. administration of c-di-AMP. 
Balb/c mice were intranasally treated with c-di-AMP (5 μg/dose; black line), MALP-2 (0.5 µg/dose; black dotted 
line) or PBS (grey shaded area). After 24 h, cells were isolated from the cLN and the expression of the surface 
markers CD80, CD86 and MHC class II was analysed on CD11c+ (DCs) or CD11b+ (MΦs) gated cells by flow 
cytometry. One representative experiment out of three is shown.     
 
 
 
3.4.2 Activation and maturation of DCs subsets in NALT and cLN after treatment 
with c-di-AMP  
The ability of c-di-AMP to stimulate in vivo DCs and their subsets was then examined. 
BALB/c mice were treated with c-di-AMP alone or co-administered with a model antigen by 
i.n. route and after 24 h the activation and maturation of DC subsets from NALT and cLN 
were analysed by flow cytometry. The obtained results showed that c-di-AMP was able to 
promote a significant increase in the expression of the co-stimulatory molecule CD86 and 
MHC-II in both cDCs and pDCs from NALT (Figure 30). Despite the observed up-regulation 
trend for CD80, the differences were not statistically significant. Co-administration of the 
adjuvant with an antigen does not affect the observed activation pattern.  
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Figure 30: Activation and maturation of DC subsets in NALT after treatment with c-di-AMP.  
BALB/c mice were treated with c-di-AMP alone or co-administered with ß-Gal by i.n. route. After 24 h, cells 
isolated from NALT  were stained and gated using markers specific for different DC subsets and further analysed 
for the expression of CD80, CD86 and MHC class II. The S.E.M. is indicated by vertical lines. Differences were 
statistically significant at p<0.001 (***), p<0.01 (**), p<0.05 (*) or non-significant (n.s.) with respect to values from 
cells of untreated BALB/c mice. One representative out of three independent experiments is shown. 
 
 
 
The DCs subset activation in cLN of c-di-AMP-treated mice was quite similar to the results 
obtained for DCs from NALT. Also here we observed a significant up-regulation of CD86 and 
MHC-II in both cDCs and pDCs (Figure 30). No significantly up-regulated expression of 
CD80 was detected after c-di-AMP treatment, and the presence of the antigen has no 
significant influence on the DC activation pattern. 
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Figure 31: Activation and maturation of DC subsets in cLN after treatment with c-di-AMP.  
BALB/c mice were treated with c-di-AMP alone or co-administered with ß-Gal by i.n. route. After 24 h cells 
isolated from cLNs the stained and gated using makers specific for different DC subsets and analysed for the 
expression of the surface markers CD80, CD86 and MHC class II. The S.E.M. is indicated by vertical lines. 
Differences were statistically significant at p<0.001 (***), p<0.01 (**), p<0.05 (*) or non-significant (n.s.) with 
respect to cells from untreated BALB/c mice. One representative out of three independent experiments is shown. 
 
 
3.5 Elucidation of the underlying mechanisms of action of c-di-AMP  
It is clear that adjuvants cannot only potentiate immune responses, but can also 
modulate them. Thus, the understanding their mechanism of action is critical to make optimal 
use of them, as well as to foresee potential safety issues. Therefore, it is important to identify 
cellular receptors and elucidate downstream signalling cascades. 
 
3.5.1 Evaluation of putative contribution of cyclic AMP to the adjuvant activity 
The c-di-AMP is formed by diadenylate cyclase (DAC) of cyclic AMP (cAMP), which is 
known to exert different effector functions on eukaryotic cells [112, 129]. For example, 
transfering the effects of hormones (such as glucagon and adrenaline), and regulating the 
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passage of Ca2+ through ion channels [36, 130]. Moreover, cAMP was shown to be involved 
in cell proliferation and the regulation of leukocytes function [131]. Thus, it was important to 
rule out if part of the observed activities of c-di-AMP can be explained by its conversion into 
cAMP. Therefore, BALB/c mice were immunized with the model antigen ß-Gal (15 µg/dose) 
alone or co-administered with either c-di-AMP or cAMP by the i.n. route. As shown in Figure 
32A, animals receiving cAMP as adjuvant showed only a marginal increase in ß-Gal-specific 
IgG-titres, as compared to animals vaccinated with the antigen co-administered with c-di-
AMP. Lymphoproliferative assays were then carried out to evaluate the capacity of cAMP to 
promote cellular immune responses. To this end, splenocytes isolated 42 days after the first 
immunization were re-stimulated in vitro with the ß-Gal protein. No proliferative responses 
were observed in cells from mice receiving ß-Gal with cAMP (Figure 32B). This data suggest 
that under these experimental conditions cAMP does not exert any strong adjuvant effect 
when administered by the i.n. route. Conversely, it seems unlikely that c-di-AMP derived c-
AMP could be responsible for the observed immune modulatory activities of c-di-AMP.  
 
Figure 32: Comparative evaluation of the adjuvant properties of cAMP and c-di-AMP in BALB/c mice 
vaccinated i.n. route. 
A) Systemic humoral immune responses stimulated in BALB/c mice vaccinated using c-di-AMP (5µg/dose) or 
cAMP (2,5µg/dose) as adjuvant. Kinetic analysis of anti-ß-Gal IgG responses in sera from BALB/c mice (n=5) 
immunized on day 0, 14 and 28 with PBS (control), ß-Gal alone (15 µg/dose) or  ß-Gal co-administered with 5 
µg/dose of either c-di-AMP or cAMP by the i.n. route. Differences were statistically significant at p<0.001 (***) or 
p<0.05 (*) with respect to values in BALB/c mice receiving antigen alone. One representative out of four 
independent experiments is shown. The results are expressed as end point titres. The S.E.M. is indicated by 
vertical lines. (B) Evaluation of the cellular immune responses stimulated in vaccinated mice. Spleen cells from 
vaccinated animals were re-stimulated with different concentrations of β-Gal for 96 h. Cellular proliferation was 
then assessed by determination of the [
3
H]-thymidine incorporated into the DNA of replicating cells. Results are 
averages of quadruplicates and they are expressed as stimulation index (SI). The S.E.M. is indicated by vertical 
lines. Differences were statistically significant at p<0.01 (**) with respect to BALB/c mice receiving antigen alone. 
One representative out of three independent experiments is shown.  
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3.5.2 Intracellular targeting of c-di-AMP 
There are different processes by which the cells can uptake substances. The two 
main forms are by endocytosis or phagocytosis. Besides the molecular signalling induced by 
c-di-AMP it is also important to understand if and how cells uptake the adjuvant. Therefore, 
the adjuvant was labelled by different methods, such as Nanogold (NG) for electron 
microscopy analysis (EM) or with the fluorescent tracer fluorescein for confocal examination.  
 
3.5.4.2. Accumulation of Nanogold-c-di-AMP in vesicles of DCs. 
To study the uptake and the detectability c-di-AMP was labelled with Nanogold and 
incubated with BMDCs for different time points. Nanogold is a small (1.4 nm) and highly 
uniform gold compound and can be used to label primary amines of c-di-AMP. In order to 
assess the significance of the resulting observations, the ability of the c-di-AMP-conjugate 
(NG-c-di-AMP) to stimulated DCs was first investigated by FACS. The c-di-AMP-conjugate 
was still able to stimulate the DCs in a comparable intensity as the non-conjugated adjuvant 
(Figure 33). 
 
 
Figure 33: The ability of NG-c-di-AMP to stimulated DCs. 
BM-derived murine DCs were incubated with NG-c-di-AMP, c-di-AMP, NG alone and medium as control for 24 h 
and analysed by flow cytometry. The expression of the co-stimulatory surface markers CD80 and CD86 on 
CD11c
+
/MHC-II
+
-gated cells is shown. The S.E.M. is indicated by vertical lines. Differences were statistically 
significant at p<0.001 (***) with respect to untreated BMDCs. One representative out of two independent 
experiments is shown. 
 
 
Next, the fate of NG-c-di-AMP in DCs was examined by EM analysis. To this end, 
DCs were incubated with the conjugate for different time intervals. The Nanogold signal was 
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enhanced with a silver developer so that the small gold particles were easily visualized by 
EM.   
 
 
Figure 34: Electron microscopy analysis of Nanogold-c-di-AMP conjugate accumulated in vacuoles of 
DCs.  
EM analyses of BMDC treated with or without NG-c-di-AMP (black arrows) for 0.5 min, 5 min and 6 h after silver 
enhancement.   
 
 
The NG-c-di-AMP conjugate was detected already after 0.5 min in the cytoplasma of 
DCs and accumulated in vesicles with increasing incubation time (Figure 34). After 6 h of 
incubation with the c-di-AMP-conjugate, DCs showed a high number of intracellular vesicles 
including the conjugate (Figure 34); however no NG-c-di-AMP could be detected in the 
nucleus.    
 
 
3.5.4.3. Examination of the intracellular targeting of 2'-Fluo-AHC-c-di-AMP in BMDCs by   
confocal microscopy  
In order to characterize the intracellular compartments in which resides the c-di-AMP, 
immune labelling experiments with antibodies directed against the early endosomes marker 
Rab5 and the late endosomal/lysosomal marker LAMP2 were undertaken. BMDCs were 
treated with the 2'-Fluo-AHC-c-di-AMP conjugate for 1 h and stained with Hoechst 33258 and 
Rab5 or LAMP2 and analysed by confocal microscopy. The obtain results confirm the EM 
5 min 6 h 
0.5 min untreated
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analysis indicating an accumulation of c-di-AMP conjugate in intracellular compartments of 
DCs after 1 h of treatment. The merged figure shows an accumulation of c-di-AMP in early 
endosomes labelled with Rab5 (Figure 35).   
 
 
 
 
 
 
Figure 35: Analysis by confocal microscopy of 2'-Fluo-AHC-c-di-AMP conjugate treated DCs using 
antibodies specific for Rab5.  
BMDCs were treated with 2'-Fluo-AHC-c-di-AMP (green) for 1 h, mounted onto slides, fixed, permeabilized, 
subjected to indirect anti-Rab5 (Cy3, red) and nuclear (Hoechst 33258, blue) immunostaining and analysed by 
confocal laser-scanning microscopy. To demonstrate the relative positional distribution of Hoechst-, Cy3- and 
FITC-labelled moieties, the images collected in the three fluorescence channels were merged. In the overlay 
mode, subcellular areas in which Cy3 and FITC fluorescence co-localize appear in yellow. 
 
 
 
The investigation of late endosomes/lysosomes also indicated an accumulation of c-
di-AMP conjugate in the LAMP2 marked vesicles (Figure 36). However, no c-di-AMP-
conjugate could be detected in the nucleus. 
 
2'-Fluo-AHC-c-di-AMP Hoechst 33258
MergeRab5
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Figure 36: Analysis by confocal microscopy of 2'-Fluo-AHC-c-di-AMP conjugate treated DCs using 
antibodies specific for LAMP2. 
BMDCs were treated with FITC-c-di-AMP (green) for 1 h, mounted onto slides, fixed, permeabilized, subjected to 
indirect anti-LAMP2 (APC, red) and nuclear (Hoechst 33258, blue) staining and analysed by confocal laser-
scanning microscopy. To demonstrate the relative positional distribution of Hoechst-, APC- and FITC-labelled 
moieties, the images collected in the three fluorescence channels were merged. In the overlay mode, subcellular 
areas in which APC and FITC fluorescence co-localize appear in yellow. 
 
 
3.5.3 Induction of type I IFN response by c-di-AMP after i.n. administration  
Several studies demonstrated that DC activation (e.g. after detection of nucleic acids 
through TLR or cytosolic sensors) can lead to type I IFN secretion. Type I IFN not only 
directly inhibits viral infection, but also activates the antiviral functions of NK cells, DCs, B 
cells and T cells, thereby playing a central role in the initiation and regulation of innate and 
adaptive antiviral immunity [132, 133]. Thus, the in vivo effect of c-di-AMP on type I IFN 
induction was studied.  
To determine the contribution of myeloid or lymphoid cell populations to the IFN-ß 
production after c-di-AMP treatment, tissue/cell subset specific reporter mice were used 
since these mice allow tissue/cell subset specific replacement of the IFN-ß gene by the 
luciferase reporter in the IFN-ß+/floxb-luc mice [134]. These mice were crossed with mice 
expressing Cre recombinase under various tissue/cell subset specific promoters. CD19cre 
mice were used to implement the reporter activity in B cells, CD4cre mice in T cells, LysMcre 
mice in monocytes/macrophages and granulocytes and CD11ccre mice in DCs. All reporter 
mice were heterozygous for both markers to allow normal cellular development as well as 
potential production of IFN-ß in all cells. Comparison of such tissue specific reporter mice 
2'-Fluo-AHC-c-di-AMP 
MergeLAMP2
Hoechst 33258
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after c-di-AMP treatment with the „„global‟‟ IFN-ß reporter mouse (IFN-ß+/Δß-luc) by whole body 
in vivo imaging demonstrated that T and B cells did not have any apparent impact on the 
IFN-ß production after i.n. administration of c-di-AMP (Figure 37). However, cells in which the 
LysM- and CD11c-promoter is active, significantly contribute to the IFN-ß signal and leads to 
a maximal IFN response 6 h after administration (Figure 37). Additionally, IFNAR-/- mice 
were used to investigate the influence of c-di-AMP on type I IFN expression. The obtained 
results revealed that c-di-AMP is triggering a strong local time-dependent induction of the 
IFN-ß genes in IFNAR-/- mice comparable to the signal of the global IFN-ß reporter mice with 
an average radiance of 105 p/sec/cm2/sr  (Figure 37B). 
 
 
Figure 37: Induction of IFN-ß genes after administration of c-di-AMP.  
Mice of indicated phenotypes in the C57BL/6 genetic background were i.n. treated with c-di-AMP (5 µg/dose):  
“global” stands for IFN-ß
+/Δβ-luc
; „„CD4‟‟, „„CD19‟‟, „„LysM‟‟ and IFNAR-/- stand for IFN-ß
+/floxb-luc
 x CD4cre, IFN-
ß
+/floxb-luc
 x CD19cre, IFN-ß
+/floxb-luc
 x LysMcre and IFNAR knock out, respectively. A) At the depicted time points 
after i.n. administration of c-di-AMP (5 µg/dose), mice were injected with luciferin (i.v.) and luciferase activity was 
visualized in the IVIS 200 imaging system. Low signals are due to quenching of the bioluminescent light by 
melanin in fur and skin of the C57BL/6 mice. B) Quantification of in vivo imaging by measuring of luminescence 
intensity of the mice with indicated phenotypes shown in A) at the depicted time points. The experiment was done 
twice with 2-3 animals per group. Results are expressed as average of radiance. S.E.M. is indicated by vertical 
lines. 
 
A
0 3 6 12 24
102
103
104
105
106
IFN-ß
+/ ßluc
LysM
CD11c
CD4
IFNAR -/-
CD19
Time [h]
A
v
e
ra
g
e
 R
a
d
ia
n
c
e
 [
p
/s
e
c
/c
m
2
/s
r]
B
   
  RESULTS 
 
85 
 
3.5.4 Phosphorylation of MAPK is activated in c-di-AMP treated MΦs and DCs  
To determine whether c-di-AMP could activate intracellular signalling, the effect of c-
di-AMP on the activation of MAPK in MΦs (the macrophage like cell line J774.A1) and 
primary BMDCs was investigated. To this end, MΦs or BMDCs were treated with 5 µg/ml of 
c-di-AMP for different time intervals (5, 20 or 30 min), the cells were then lysed and a 
Western blot based on the Proteome Profiler Human Phospho-MAPK Array was performed.  
The results showed a phosphorylation of extracellular signal-regulated kinase 1/2 
(ERK 1/2), and p38α MAPK (MAPK14) even 5 min after c-di-AMP stimulation of MΦs. These 
levels of phosphorylation gradually decreased 20 and 30 min after treatment. Further MAPKs 
such as Jun N-terminal kinase1 (JNK1) and JNK2 were slightly increased after 5 and 20 min. 
However, phosphorylation of JNK3, p38ß, γ and δ MAPK was not detected in MΦs at all 
(Figure 39).  
 
 
Figure 38: c-di-AMP induces MAPK signalling in macrophages.  
Activation of MAPK pathways in a macrophage cell line (J774A.1). MΦs were incubated in the absence or 
presence of c-di-AMP (5 µg/ml) for 5 min, 20 min or 30 min. Following exposure to c-di-AMP, MΦs were 
harvested to make cell lysates. Identical amount of cell lysates was separated on a membrane and analysed by 
Western blot based Proteome Profiler Human Phospho-MAPK Array Kit.  
 
The analysis of phosphorylated MAPK in cDCs showed also a slight activation of the 
p38α MAPK 5 min after stimulation with c-di-AMP, with the level of phosphorylation 
increasing strongly after 20 min and decreasing slightly at 30 min. However, the 
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phosphorylation of ERK1/2 is shown to be only slightly activated 30 min after c-di-AMP 
treatment. A marginal phosphorylation is also seen in JNK1 and 3, p38ß, γ and δ MAPK after 
30 min of stimulation (Figure 39). Other proteins, such as JNK2, showed suppression after 
the stimulation with c-di-AMP. In general, the MAPK phosphorylation in MΦs is much 
stronger than in DCs after stimulation with c-di-AMP, and distinct patterns were observed in 
each cell type. The rapid modification of the phosphorylation pattern suggests that a direct 
rather than an indirect mechanism relaying on gene activation is responsible for the observed 
changes.    
 
 
Figure 39: c-di-AMP induces MAPK signalling in cDCs.  
Activation of MAPK pathways in a BMDCs. DCs were incubated in the absence or presence of c-di-AMP (5 µg/ml) 
for 5 min, 20 min or 30 min. Following exposure to c-di-AMP DCs were harvested to make cell lysates. Identical 
amount of cell lysates was separated on a membrane and analysed by Western blot Western blot based 
Proteome Profiler Human Phospho-MAPK Array Kit. 
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4. CHAPTER: DISCUSSION 
 
4.1. Cyclic di-nucleotides exhibit high potential as adjuvants for the 
development of mucosal vaccines. 
 
4.1.1. Requirement of new adjuvants  
In recent years we have assisted to the advent of new approaches and technologies, 
which have in turn facilitated the identification of candidate antigens for developing novel 
subunit vaccines. For example, the promising genomic-based approach known as “reverse 
vaccinology” has been exploited to identify antigens, which have been translated into the 
clinical development pipeline [135-139]. Thus, in the post-genomic era the identification of 
suitable candidate antigens does not represent a major bottleneck any longer. However, 
subunit vaccines are poorly immunogenic, raising the need for adjuvants able to promote the 
elicitation of responses of appropriate quality and strength. Therefore, it is becoming obvious 
in the field of vaccinology that for vaccine development, the availability of an optimal adjuvant 
is as important as the selection of the antigen. This need is becoming more pressing when 
issues such as antigen sparing in the context of pandemic threats, immune modulation for 
therapeutic vaccines, or vaccines tailored for specific population groups (e.g. new-borns, 
elderly) are considered.  
 Most pathogens enter the host via the mucosal tissues; however, most 
licensed vaccines are administered via parenteral route [51]. This approach mainly leads to 
the elicitation of systemic responses. Thus, it is not possible to block the agents at the portal 
of entry, thereby reducing their capacity to colonize the host. Hence, the induction of immune 
responses at both systemic and mucosal levels represents a major asset for a vaccine 
against a pathogen which is restricted to, or need to transit across the mucosa in order to 
cause disease. In fact, the efficient stimulation of immune responses at the portal of entry 
would not only prevent disease, but also infection (i.e., colonization). In addition, vaccination 
by the mucosal route is more accepted by the public and it is associated with a lower risk for 
cross contamination or appearance of side effects [140]. This can be achieved by 
administering the antigens by a mucosal route. However, purified antigens are even less 
immunogenic when administered by this route, due among other reasons, to their clearance, 
degradation and/or poor penetration [141]. This bottleneck can be overcome by the use of 
mucosal adjuvants. However, there are even less candidate adjuvants exhibiting this feature.  
The mucosal immune system is compartmentalized and there is no physical 
connection between different mucosal territories [52]. Nevertheless, our current knowledge 
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on the structure and function of the mucosal immune system, the interplay between its 
cellular components, the role of locally produced soluble mediators, the linkage between 
different mucosal niches in a fully integrated network and their bridging with the systemic 
compartment are, at the very best, incomplete. Therefore, it is critical to elucidate the 
underlying mechanisms to the elicitation of immune responses following vaccination by the 
mucosal route. This would allow exploiting the full potential of this strategy for the 
establishment of prophylactic and therapeutic interventions against infectious and non-
infectious diseases.  
Promising mucosal candidate adjuvants are the second messengers c-di-GMP, c-di-
AMP and c-di-IMP (Figure 3). The c-di-GMP was first identified in Gluconacetobacter xylinus 
as a secondary metabolite involved in the regulation of cellulose production [98]. Additional 
studies by Karaolis et al. and other groups showed that exogenous c-di-GMP reduces in vitro 
cell-cell interactions and biofilm formation of S. aureus and also demonstrated that treatment 
with c-di-GMP attenuates S. aureus infection in vivo in a mouse model [102, 103, 108, 142-
144]. Unexpected, they found that c-di-GMP has no apparent inhibitory or bactericidal effect 
on S. aureus in vitro, thereby suggesting that the observed reduction in colonization by 
biofilm-forming S. aureus strains was due to a biological effect on the host immune system 
[110, 145]. In fact, in this doctoral thesis it is shown that in vitro, c-di-GMP and to a greater 
extent c-di-AMP stimulates the production of nitric oxide by pre-activated murine 
macrophages at a concentration of 200 and 1.6 ng/ml, respectively (Figure 6).  
Subsequent reports described another compound of the cyclic di-nucleotide family, c-
di-AMP (Figure 3), which serves as a second messenger signalling for DNA integrity in B. 
subtilis during sporulation [129]. Additional studies showed that c-di-AMP is widespread in 
bacteria and archaea, suggesting that this compound may act as a second messenger in 
response to various cues besides branched DNA [112]. More recently, Woodward et al. 
identified c-di-AMP as a secreted molecule by L. monocytogenes, which is able to trigger the 
cytosolic host response of innate immunity [113]. Since they seem to be crucial for several 
key bacterial processes, it can be assumed that these molecules could serve as danger 
signals recognized by the host immune system. It can be also argue that other structurally 
related, although chemically distinct compounds could also act as danger signals able to 
evoke an immune response in the host. An example of this is the c-di-IMP (Figure 3), which 
was synthesized out of the parental compound c-di-AMP through adenosine-deaminase.  
 An in depth side-by-side characterization of the immune modulatory properties of 
the three second messengers c-di-GMP, c-di-AMP and c-di-IMP after mucosal administration 
was therefore performed. In the focus of this doctoral thesis was first the identification of the 
effector functions of the three cyclic di-nucleotides and their potency as mucosal adjuvants to 
select the most promising compound for further development (i.e. c-di-AMP). Second, the 
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analysis of the targeted cells and effector functions. Third, the identification of the underlying 
mechanisms of action and/or putative molecules involved in the signalling transduction 
events leading to the exertion of its adjuvant properties. To this end, the in vitro and in vivo 
influence of c-di-AMP on the activation and maturation of different immune cells was 
investigated (e.g., DCs, MΦs, B cells, T cells). 
 
4.1.2. Stimulation of antigen-specific immune responses by the c-di-nucleotides  
In vivo studies were carried out to evaluate their adjuvant capacities using ß-Gal or 
OVA as model antigens. The presence of c-di-GMP, c-di-AMP or c-di-IMP in the formulation 
resulted in a significantly improved stimulation of antigen-specific immune responses at 
mucosal level. More specifically, high titres of ß-Gal-specific IgG were detected in sera of 
mice vaccinated with c-di-AMP (>1:6,000,000), c-di-GMP (1:4,000,000) or c-di-IMP 
(1:3,500,000) as adjuvants in comparison to sera from control mice receiving ß-Gal alone 
(<1:2,000), as shown in Figure 7. Analysing sera and lavage samples of C57BL/6 mice 
vaccinated with OVA alone or co-administered with c-di-AMP, c-di-GMP or c-di-IMP elevated 
a comparible antigen-specific IgG and IgA expression (Figure 11). Furthermore, the co-
administration of c-di-nucleotides resulted in enhanced antigen-specific mucosal immune 
responses, not only locally in the nose or lung, but also at distant mucosal territories, such as 
in vaginal secretions (Figure 8). Similar results were obtained when a SC-specific ELISA was 
implemented to rule out that the obtained results were in part derived from Ig transferred into 
the lumen by transudation. This suggests that efficient activation, migration and homing of 
precursors are taking place.  
Cellular proliferative responses were also enhanced in mice vaccinated using c-di-AMP 
(SI >20), c-di-IMP (SI >14), or c-di-GMP (SI > 7) with respect to those receiving the ß-Gal 
antigen alone (SI <3; Figure 9). The analysis of sera from animals vaccinated with the cyclic 
di-nucleotides revealed the presence of high ß-Gal specific IgG1 titres, thereby indicating the 
stimulation of Th2 cells. However, significant levels of antigen-specific IgG2a were detected 
in sera, suggesting that Th1 cells are also activated (Figure 12). Moreover, the evaluation of 
the cytokines secreted by lymphoid cells from vaccinated mice showed that vaccination using 
c-di-nucleotides as adjuvants resulted in an enhanced secretion of IL-2, IL-4, IL-17 and IFN-y 
(Figure 13). Re-stimulated splenocytes derived from mice receiving c-di-nucleotides also 
showed an enhanced expression of soluble factors such as IFN-y, TNF-α, IL-2, IL-1, IL-4 IL-5 
IL-6 and IL-10 which act as attractants of naïve and effector T cells, as well as inducers of T 
cell differentiation (e.g. IL-17). IL-17 is a key molecule in the recruitment of neutrophils and 
DC maturation [54-60]. This explains at least in part the observed immune potentiation with 
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enhanced maturation of various cell subsets, promotion of T cell polarization and 
development of B cells.  
Taken these results together, c-di-GMP, c-di-AMP and c-di-IMP induced a balanced 
Th1/Th2/Th17 response pattern. This profile is particularly attractive, since most adjuvants 
described up to now promote either Th1 or Th2 biased responses. The stimulation of a more 
balanced Th1/Th2/Th17 pattern after immunization with cyclic di-nucleotides as adjuvants, 
suggests that they are more flexible molecules, which would allow fine-tuning immune 
responses in the context of a broader range of clinical applications. 
Although cyclic di-nucleotides have similarities in some general features of their 
molecular structure, there are clear chemical and biological differences that make each of 
them a unique compound. Beyond their being distinct chemical entities, the in vivo studies 
show the stimulation of a balanced Th1/Th2/Th17 immune responses after the administration 
of the c-di-nucleotides by intranasal route. However, there are also some differences in the 
potency of these small molecules, suggesting that c-di-AMP exerts the most potent adjuvant 
activity. This is further supported by the distinct functional biological properties of cyclic di-
nucleotides observed on pre-activated macrophages in vitro (Figure 6). Moreover, microarray 
studies performed with MΦs stimulated with cyclic di-nucleotides revealed a distinct 
transcriptional profile suggesting a different mode of actions (data not shown). The balance 
between differences in structure and effector functions needs further elucidation in order to 
exploit these compounds for fine-tuning responses to vaccine antigens.  
 
4.1.3. The novel adjuvant c-di-AMP is acting preferentially plainly on DCs  
Stimulation of innate immunity is initiated by the interaction of PAMPs with PRR, 
present on immune cells [146]. Of special importance are the professional APCs - MΦs, DCs 
and B cells – which initiating the cascade of events that result in the development of 
immunity [147, 148]. Professional APCs express a wide variety of PRR. These receptors are 
used as sensors for pathogens and also sample antigens in their microenvironment. Binding 
of PAMPs by PRR induces a DC activation that comes along with the up-regulation of MHC 
antigens and co-stimulatory molecules, such as CD40, CD80 and CD86 [149]. The up-
regulation of these molecules is accompanied by the differentiation of immature into mature 
DCs, MΦs or B cells [150].  
When investigating the effect of c-di-AMP on mouse DCs, MΦs and splenic B cells in 
vitro, a clear up-regulation of activation markers has been observed in DCs and MΦs, but not 
in B cell (Figure 16 and 17). Thus, exogenous administered c-di-AMP seems to have a 
strong impact on the maturation and activation of DCs and MΦs, thereby leading to a 
downstream signalling which was expected to result in improved innate and adaptive 
   
  DISCUSSION 
 
91 
 
immunity. More important, this is not restricted to the murine system, since it could be 
demonstrated that human immature DCs and MΦs stimulated with c-di-AMP strongly 
increase the expression of maturation and activation markers (MHC-II, CD80/CD86, CD83; 
Figure 26). This makes c-di-AMP a true candidate adjuvant for clinical use in humans.        
Following maturation, DCs play an important role in the activation of both the innate 
and adaptive immune system. After sampling antigens in the periphery and activation, 
mature DCs migrate to secondary lymphoid tissues, where they interact with different 
immune cells, thereby leading to the activation of lymphocytes and the stimulation of antigen-
specific adaptive responses. In fact, co-stimulatory and adhesion molecules represent critical 
co-receptors for T cell priming in the context of both MHC class I and II molecules [151]. DC 
activated T cells can complete the immune response by interacting with other immune cells, 
such as B cells for antibody formation, macrophages for cytokine release, and targets for 
lysis [150]. The investigation of the capacity of murine and human c-di-AMP-stimulated DCs 
to activate T cells resulted in an enhanced proliferation of both CD8+ and CD4+ T cells 
(Figure 19 and Figure 27). However, as expected and desired, no direct induction of murine 
T cells could be observed after c-di-AMP treatment (Figure 20). The excellent performance of 
c-di-AMP in in vitro experiments led us to performing studies to assess the effector functions 
of c-di-AMP on DCs and MΦs in vivo. The results obtained in mice treated by i.n. route with 
c-di-AMP for 24 h showed an activation and maturation of DCs and, to a lesser extent, MΦs 
(Figure 28 and Figure 29).  
The two major DC subsets in mice are CD11b+, CD11c+ cDC and CD11b-, B220+ 
pDC. The examination of these DC subsets in vitro showed a stimulation of all subsets, cDCs 
(mDCs and lDCs) and pDCs, after the treatment with c-di-AMP. However, cDCs showed a 
much higher up-regulation of the co-stimulatory molecules of the B7 family (CD80 and CD86) 
than pDCs (10 versus 1.5 fold, respectively). Nevertheless, the in vivo results showed an up-
regulation of CD86 and MHC-II in both cDCs and pDCs from NALT and cLN after i.n. 
administration of c-di-AMP (Figure 30 and Figure 31).  
Mature DCs release large amounts of cytokines, such as IL-12 or IL-10, which shape 
the local microenvironment and can promote the development of Th1 and Th2 immune 
responses, respectively [147, 152]. The ability of c-di-AMP to stimulated DCs resulted in a 
high intracellular production of IL-12p40. It seems that cDCs are the main IL-12 producers 
after c-di-AMP stimulation, since they showed a 60-fold higher IL-12 production than pDCs. 
The IL-12 production appears to be c-di-AMP dose-dependent, being apparently CD8α+ DCs 
(lDCs) the main producers (Figure 24). However, IL-12 production can be affected by 
exogenous factors, such as microbial infections or stress, suggesting that IL-12 production 
strongly depends upon the general status of the environment in which DCs are located [153]. 
Furthermore, it is theoretically possible, because IL-12p40 is produced in large excess 
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compared with IL-12p35, that it is used to form IL-23 [39]. Follow up studies have 
subsequently shown that IL-23 is in fact, functionally distinct from IL-12, as it not only acts on 
Th1 cells, but also stimulates Th17 cells to produce IL-17 [39]. This might in part explain the 
observed induction of Th17 cells.  
On the other hand, IL-10 is a potent anti-inflammatory cytokine that can act as a 
feedback regulator of the inflammatory response to many microbial stimuli [154]. In addition, 
IL-10 can inhibit or modulate the release of IL-12 and the effect of IL-12 on T cells, thereby 
down-regulating Th1 responses. The balance between IL-10 and IL-12 is therefore important 
in the induction of T cell immunity [155, 156]. Interestingly, the intracellular IL-10 production 
on cDCs showed a 2-fold increment after c-di-AMP treatment in respect to untreated DCs 
(Figure 25). These investigations are consistent with the obtained balanced Th1/Th2 immune 
response.      
 
4.1.4. Putative mechanism of action of c-di-AMP 
During the last years, it became clear that adjuvants cannot only potentiate immune 
responses, but can also modulate them. Thus, the understanding their mechanism of action 
is critical to make optimal use of them, as well as to foresee potential safety issues. 
Therefore, it is important to identify cellular receptors and elucidate downstream signalling 
cascades. Although there is an increasing body of experimental evidence dissecting the 
signalling events triggered by c-di-nucleotides in prokaryotes [105-107, 112, 157, 158], much 
less is known about the effector functions on immune cells. Initial experiments performed by 
Karaolis et al. using TLR-expressing cell lines suggested that immune activation by c-di-GMP 
does not involve TLRs 1–9 or NODs 1 and 2 [111]. This was further confirmed by both in 
vitro studies showing the independency of TLR and RLR signalling by using MyD88/TRIF 
(Myeloid differentiation primary response gene 88/toll-interleukin-1 receptor [TIR]-domain-
containing adapter-inducing interferon-ß) and MAVS (mitochondrial antiviral signalling) 
deficient macrophages [159], and in vivo immunization studies using MyD88 and TIRAP 
(TIR-domain containing adaptor protein) knockout mice (unpublished data). On the other 
hand, the potential contribution of the NOD-like receptor pathway was ruled out by the intact 
responsiveness of macrophages from mice deficient for Rip2 -/-, Nalp3 -/- and Nod1/2 -/- to 
c-di-GMP [159].  Additional work suggested that c-di-GMP can be acting, at least in part, by a 
novel mechanism leading to transcriptional activation of type I IFN via CSP [159]. 
Interestingly, studies on L. monocytogenes secreted c-di-AMP also showed TLR and RLR 
independency and postulated a comparable induction of host CSP [113]. The CSP was 
initially described as an innate host surveillance mechanism, which specifically distinguishes 
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bacteria in the cytosol from bacteria in the vacuole, leading to the up-regulation of IFN-ß 
[160-162]. 
Several studies demonstrated that DCs can detect nucleic acids through TLR or 
cytosolic sensors, thereby resulting in the expression of type I IFN [133, 163]. Type I IFNs 
derived from pDCs do not only directly inhibit viral infection, but also activate the antiviral 
functions of other DC subsets, NK cells, B cells and T cells, thereby initiating and 
orchestrating innate and adaptive antiviral immunity [132, 133]. Furthermore, type I IFNs 
increase the ability of DCs to cross-present exogenous antigens to CD8+ T cells and promote 
their clonal expansion [164, 165], as well as their capacity to induce the differentiation of 
naive T cells into Th cells [166]. Therefore, c-di-AMP was investigated for its ability to induce 
type I IFNs following i.n. administration. The obtained data revealed a very fast induction of a 
reporter for type I IFN-β genes 6 h after treatment. Furthermore, by a genetic approach the 
cells that are responsible for IFN-ß production during intranasal c-di-AMP treatment were 
investigated. It was shown that IFN-ß is almost exclusively produced by CD11c+ and LysM 
expressing cells in the nasal cavity (Figure 37). Other mice, such as CD19cre mice used to 
implement the reporter activity in B cells, and CD4cre mice in T cells did not show any IFN-ß 
production after c-di-AMP treatment. Furthermore, these studies show that in the absence of 
the IFNAR component, there is still an IFN-ß signalling after the treatment with c-di-AMP, 
which is as strong as the signalling in global reporter mice. This positive feedback can be 
due to the fact that c-di-AMP is utilizing some factors or pathways stimulating the type I IFN 
response such as IRF-3, as reported by Woodworth et al. [113]. Further in vivo analyses 
would be necessary for the understanding of the functions of c-di-AMP in the context of type I 
IFN signalling. Hence, treatment with c-di-AMP not only activates DCs, but also triggers type 
I IFNs. This would in turn strengthen its potential as adjuvant at both systemic and mucosal 
level. However, the use of the LysMcre mouse does not allow distinction between myeloid 
cell populations, although lower expression in CD11c+ cells was reported [167]. 
Nevertheless, the global emerging picture from these findings confirms the further results 
showing that c-di-AMP is primary targeting DCs but also MΦs. Thus, c-di-AMP can be 
considered as a danger signal which triggers a cascade of immune signals, thereby leading 
to improved innate and adaptive immunity.  
Interestingly, there are in vitro studies showing the induction of similar transcriptional 
profiles in cells stimulated by cyclic di-nucleotides and DNA. Both are able to trigger type I 
IFNs and co-regulated genes via induction of Tank-binding kinase 1 (TBK1) and its substrate 
the IRF-3, as well as nuclear factor NF-kB and MAP kinases [113, 159, 168]. On the other 
hand, in vivo studies showed that c-di-GMP activates both IRF-3 and IRF-7 [159]. However, 
cyclic di-nucleotides are not signalling through the cytosolic DNA sensor DAI (DNA-
dependent activator of IRFs) [29, 147], as it is the case for DNA (Figure 39). Thus, great 
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importance should be attached to the MAPK signalling pathways, which play important roles 
in many cellular processes, including growth, differentiation, apoptosis, and the stimulation of 
immune responses. It has been reported by McWhirter et al. that c-di-GMP is able to activate 
all three MAPK pathways in mouse bone marrow macrophages, the ERK, p38 kinase, and 
JNK [147]. Interestingly, activation of the p38 kinase is also required for the induction of gene 
expression by the CSP. Studies shown in Figure 34 demonstrated that stimulation with c-di-
AMP of the murine macrophage-like cell line J774A.1 also results in the activation of p38α 
MAPK, ERK, and JNK kinases. In contrast, analysis of MAPK of cDCs resulted in a much 
lower phosphorylation level of p38α MAPK, followed by slightly activated ERK and even a 
suppression of JNK (Figure 39). More interestingly, the activation of MAPK was induced later 
in cDCs than in MΦs. However, these are preliminary results, it would be necessary to 
confirm them by more in depth analysis, for example with the BD™ Phosflow technology, 
which makes it possible to reveal intracellular data on protein phosphorylation by flow 
cytometry. This could in turn close the circle, since protein kinases are involved in type I IFN 
signalling, and deliver anti-apoptotic and pro-survival signals [158]. Recent studies showed 
that an ER-localized stimulator of interferon genes (STING) is required for the type I IFN 
response to c-di-GMP (both in vitro and in vivo) and c-di-AMP (only tested in vitro) [159, 
160]. Former studies showed that the STING protein is critical for regulating the production of 
IFN in response to cytoplasmic DNA virus [161] (Figure 40). 
Although there are several distinct subtypes of DCs, they all share key features. 
Namely, they continuously sample their surroundings ingesting antigens by endocytosis 
(using phagocytosis, receptor-mediated endocytosis, and pinocytosis) [22-24]. As it was 
reported in the studies on L. monocytogenes secreted c-di-AMP in the cytosol, we performed 
detection studies of the adjuvant in DCs [113]. The electron microscopic analysis showed a 
time-dependant increment of c-di-AMP aggregation in the cytosol, mostly in vesicles. 
Importantly, no c-di-AMP could be detected on the surface during the first 5 min (Figure 34), 
suggesting that the adjuvant is not binding to any surface receptor, which means that the 
molecule is probably passing the membrane or is taken up by pinocytosis. Moreover, no c-di-
AMP could be detected in the nucleus. The confocal analyses confirm the EM data, showing 
that c-di-AMP aggregates in vacuoles containing endosomal and lysosomal markers (Figure 
35 and Figure 36). Endocytosis signalling was originally viewed as a mechanism that 
delivered receptors to degradation or recycling pathways. It is now clear that diverse families 
of receptors can signal from the endosomal network to control essential cellular processes 
[169]. These endosomal signals differ from those originating from receptors located on the 
plasma membrane, both mechanistically and temporally, and endosomal signalling is tightly 
regulated by mechanisms that are not fully understood. Moreover, late endosomes have 
been proposed to serve as a site of assembly of signalling complexes that do not contain 
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receptors [170]. For example, the MAP kinase scaffold protein MP1, capable of binding to 
MEK1 and ERK1/2, is associated with the late endosomal protein p14 [91]. Knockdown of 
p14 in human cells and knockout of p14 in mouse demonstrated the importance of this 
protein for full activation of ERK1/2 [91, 171]. However, further experiments are needed to 
examine the signalling molecules in the vesicles of c-di-AMP-treated DC, as well as for 
identifying the binding partners of c-di-AMP.  
 
Figure 40: Putative intracellular cascades activated by cyclic di-nucleotides. 
In this schematic representation, TLRs are separated in two major groups, those associated to the 
membrane and those located in the endosomal compartment. For the sake of clarity, in this scheme 
there is no discrimination between the different TLR at either the membrane or endosomal 
compartment. The membrane-bound TLRs (TLR-1, TLR-2/1, TLR-2/6, TLR-4 and TLR-5) detect 
PAMPs and DAMPs on the cell surface and bind to specific TIR domain containing adapters, such as 
TRIF, MyD88, TIRAP and TRAM. Other TLRs, such as TLR-3, TLR-7 and TLR-8, are localized in 
intracellular vesicles and recognize RNA, whereas the intracellular TLR-9 recognizes DNA. The 
important players downstream in these signalling cascades are TRAF6, TAK1 and TBK1, which in turn 
phosphorylates IRF-3 and IRF-7, leading to their homo-dimerization and translocation into the 
nucleus, where they drive transcription of IFNs. This signalling cascades result in the activation of NF-
kB and MAPK, which in turn are leading to the production of pro-inflammatory cytokines and type I 
IFN. On the other hand, TLR-independent recognition of PAMPs is mediated by the intracellular 
receptors NLRs (NODs) and RLRs (RIG-I, MDA-5) present in the cytosol, which after activation trigger 
a subset of responses, which are similar to those promoted by TLRs. Exogenous or viral dsRNA is 
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recognized by the RNA helicase RIG-I (or MDA-5), and signals through the mitochondrial antiviral 
signalling adaptor MAVS (also known as IPS-1), which activates TBK1, thereby leading to 
phosphorylation of IRF-3, NF-kB release, translocation of the transcriptional regulators and gene 
induction. DNA is sensed by DAI, leading to activation of the same TBK1/IRF pathway as RIG-I/MDA-
5. The ER-localized STING protein was shown to be critical for regulating the production of IFN in 
response to cytoplasmic DNA virus. In vitro and in vivo studies suggest that c-di-AMP are sensed 
through a cytosolic pathway leading to type I IFN induction. The induction of type I IFNs by c-di-
nucleotides is dependent on TBK1/IRF-3 signalling, although it is independent of known cytosolic 
receptors. The adaptor molecule STING also seems to be required for the type I IFN responses 
induced by c-di-nucleotides. Red lines: putative c-di-nucleotide driven pathways for which strong 
experimental evidence exists. Black lines: non c-di-nucleotides driven pathways. 
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CONCLUSIONS 
 
The emergence of many infectious diseases together with the unavailability of 
adequate therapeutic options emphasizes the need for developing new or more efficient 
vaccines. Modern subunit vaccines are poorly immunogenic and demand the incorporation of 
adjuvants in the formulation to improve the immunogenicity of purified antigens. In this thesis, 
it was demonstrated that the cyclic di-nucleotides c-di-GMP, c-di-AMP and c-di-IMP are 
promising candidates as mucosal adjuvant. It was shown that i.n. immunization with cyclic di-
nucleotides co-administered with model antigens promotes the stimulation of a mixed 
Th1/Th2/Th17 immune response. The experiments presented here have also shown that c-
di-AMP is giving a stronger immune response in comparison to c-di-GMP or c-di-IMP. In vitro 
studies showed a strong impact of c-di-AMP on both murine and human DCs. More in depth 
analysis revealed a strong up-regulation of activation markers of murine cDCs, both in vitro 
and in vivo, indicating them as a primary cell target. Functional studies on the mechanism of 
action showed that c-di-AMP is located in a vesicular compartment of DCs and that it is able 
to trigger the induction of IFN-ß and IL-12 production by DCs and MΦs. The observed 
activation of MAPK pathways (e.g. p38α, MAPK, ERK), suggests these pathways can be 
regulated by intravesicular signaling of the adjuvant. The possibility to generate synthetic 
cyclic di-nucleotides as well-defined chemical entities opens new ways to stimulate a broad 
spectrum of effector cells and clearance mechanisms following vaccination by the mucosal 
route. Up to now, preclinical studies suggest that cyclic di-nucleotides would also exhibit an 
adequate safety profile; however, their true potential in terms of safety and efficacy for 
human vaccine development remains to be proven in the field. 
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